CINXE.COM

<!doctype html><html class="mobile-web-player" lang="en" dir="ltr"><head><meta charSet="utf-8"/><title>Episode 6. Entrepreneur Spotlight: Rukiyah Van Dross-Anderson, Claradele Pharmaceuticals - SBIR Innovation Lab | Podcast on Spotify</title><meta property="og:site_name" content="Spotify"/><meta property="fb:app_id" content="174829003346"/><link rel="icon" sizes="32x32" type="image/png" href="https://open.spotifycdn.com/cdn/images/favicon32.b64ecc03.png"/><link rel="icon" sizes="16x16" type="image/png" href="https://open.spotifycdn.com/cdn/images/favicon16.1c487bff.png"/><link rel="icon" href="https://open.spotifycdn.com/cdn/images/favicon.0f31d2ea.ico"/><meta http-equiv="X-UA-Compatible" content="IE=9"/><meta name="viewport" content="width=device-width, initial-scale=1"/><link rel="preload" href="https://encore.scdn.co/fonts/SpotifyMixUI-Regular-cc3b1de388efa4cbca6c75cebc24585e.woff2" as="font" type="font/woff2" crossorigin="anonymous"/><link rel="preload" href="https://encore.scdn.co/fonts/SpotifyMixUITitleVariable-8769ccfde3379b7ebcadd9529b49d0cc.woff2" as="font" type="font/woff2" crossorigin="anonymous"/><link rel="preload" href="https://encore.scdn.co/fonts/SpotifyMixUITitle-Bold-37290f1de77f297fcc26d71e9afcf43f.woff2" as="font" type="font/woff2" crossorigin="anonymous"/><link rel="preload" href="https://encore.scdn.co/fonts/SpotifyMixUI-Bold-4264b799009b1db5c491778b1bc8e5b7.woff2" as="font" type="font/woff2" crossorigin="anonymous"/><link rel="preload" href="https://encore.scdn.co/fonts/SpotifyMixUITitleVariable-8769ccfde3379b7ebcadd9529b49d0cc.woff2" as="font" type="font/woff2" crossorigin="anonymous"/><link rel="preload" href="https://encore.scdn.co/fonts/SpotifyMixUITitle-Extrabold-ba6c73cd7f82c81e49cf2204017803ed.woff2" as="font" type="font/woff2" crossorigin="anonymous"/><meta name="description" content="Listen to this episode from SBIR Innovation Lab on Spotify. NCI SBIR Director Michael Weingarten and Rukiyah Van Dross-Anderson, Founder and CEO of SBIR-funded Claradele Pharmaceuticals discuss the journey from postdoc to biotech startup and how women and underrepresented entrepreneurs with innovative cancer solutions can also leverage SBIR support to move their ideas forward. Listen to this podcast to hear: • Stages of product development (fundraising rounds, company collaborations, team culture development, and more) • Lessons Learned when transitioning from academia to the early stages of product commercialization • Benefits of contacting program directors when applying for SBIR/STTR opportunities • Coaching received through the Applicant Assistance Program • Utilizing state biotech professional organizations • Programs early-stage businesses can use Podcast Guest Speakers: Name Bios Michael Weingarten, MA Director SBIR Development Center National Cancer Institute In this role, Michael Weingarten leads a team of nine Program Directors who manage all aspects of the NCI SBIR & STTR Programs including a portfolio of $182M in grants and contracts annually. The SBIR & STTR programs are NCI's engine of innovation for developing and commercializing novel technologies and products to prevent, diagnose, and treat cancer. Weingarten has implemented a set of key initiatives for optimizing the performance of the NCI SBIR Program at the NIH. These include the establishment of a new model at the NCI for managing the program - the SBIR Development Center. Rukiyah Van Dross-Anderson, PhD Founder and CEO Claradele Pharmaceuticals Rukiyah T. Van Dross-Anderson, PhD is the CEO and founder of NCI SBIR-funded therapeutics company, Claradele Pharmaceuticals. Her work began at East Carolina University, where she is an associate professor and the director of Graduate Programs, Pharmacology & Toxicology Concentration. Dr. Van Dross-Anderson is working to develop an effective and non-toxic drug as an alternative therapeutic regimen for melanoma patients who aren’t responsive to traditional treatments. To attract third-party investors that would help get her innovation to get to the patients that need them, Dr. Van Dross-Anderson is working through proof-of-concept studies to demonstrate her innovation’s commercial viability. Through her participation in the NCI SBIR program, she used funding to scale up production and received entrepreneurial mentorship to navigate the complex business world. Dr. Van Dross-Anderson graduated from Rutgers University, UMDNJ-RWJMS with a doctoral degree in Molecular and Cellular Pharmacology. Programs referenced in this episode: • Minority Biomedical Research Symposium (MBRS) program - http://mbrs.newark.rutgers.edu/ • Minority Access to Research Careers - https://www.nigms.nih.gov/training/MARC/Pages/USTARAwards.aspx • Applicant Assistance Program - https://sbir.cancer.gov/small-business-funding/application-process/applicant-assistance • I-Corps at NIH program - https://sbir.cancer.gov/commercialization/business/icorps • NCI SBIR Women’s Innovation Network • Office of technology transfer (offered at most school) • NCI SBIR Investor Initiative - https://sbir.cancer.gov/commercialization/business/investor-initiatives • Small Business Transition Grant - https://sbir.cancer.gov/small-business-funding/grants/small-business-transition Transcript: KEY: MICHAEL = Michael Weingarten, RUKIYAH = Dr. Rukiyah Van Dross-Anderson [music] MICHAEL: Hello and welcome to Innovation Lab, your go to resource for all things biotech startups, brought to you by the National Cancer Institute’s Small Business Innovation Research, SBIR Development Center. Our podcast hosts interviews with successful entrepreneurs and provides resources for small businesses looking to take their cutting edge cancer solutions from lab to market. I'm Michael Weingarten, the director of NCI SBIR and today's host. Today, in celebration of the Women's History Month, I'm excited to introduce our listeners to one of our women awardees, Dr. Rukiyah Van Dross-Anderson. Rukiyah is the CEO and founder of an NCI SBIR funded therapeutics company Claradele Pharmaceuticals. Her work began at East Carolina University where she is an associate professor and the Director of Graduate Programs, Pharmacology and Toxicology Concentration. Dr. Van Dross-Anderson is working to develop an effective and non-toxic drug as an alternative therapeutic regimen for melanoma patients who aren't responsive to traditional treatments. We will discuss her journey from post-doc to biotech startup, and share how women and underrepresented entrepreneurs with innovative cancer solutions can also leverage SBIR support to move their ideas forward. Welcome, Rukiyah. RUKIYAH: Thank you. Thank you for having me. MICHAEL: Can you kind of walk us through the arc of your career and how your company Claradele was formed? RUKIYAH: Oh, sure. So my research career began at Alabama State University, where I was a chemistry major, and through the university, I participated in some really important programs that helped me to understand that I really love research. So as an undergraduate, I was in the MBRS program, which stands for a Minority Biomedical Research Symposium. I was also a MARC student, Minority Access to Research Careers, and these two programs were NIH-funded programs that gave undergraduate students an opportunity to experience research. And it's through that experience that I found my true love, which is research. So after graduation from my undergraduate institution, I did two post-docs, one at Vanderbilt University and the other at the University of Kansas Medical Center. It was there that I honed my skills and really learned how to become a cancer researcher. From there I became part of the faculty at East Carolina University as an assistant professor, and I'm now an associate professor. And so throughout these years, I was really focused on developing novel agents that were effective against cancer. And so through this process, we discovered a novel molecule which we obtained a patent for to use as a therapeutic for melanoma and other types of cancer. And so thereafter the question was, what do we do next? What do we do with this molecule that we've patented and how do we get it to the stage where the public has access to it or the public can use this therapeutic? And so to kind of answer that question, I started attending different workshops that discuss the different options or the different ways in which drugs can be commercialized. And through this experience, I chose to form my biotech company, which is called Claradele Pharmaceuticals, and this company was founded in 2020. MICHAEL: Got it. So you've really had an interesting journey. You know, based on the research and then deciding to start Claradele. Can you maybe tell us a little bit more about the product and the technology that you've been working on, with funding that we've been providing from NCI SBIR? RUKIYAH: Sure. Yeah. So what we're working on is developing a small molecule therapeutic. And this agent has the ability to kill melanoma cancer cells and also stimulate the immune system. So the action of cancer killing and stimulating the immune system are really critical for effective tumor eradication. And our data, thus far, indicates that we have an agent with unique and promising properties that has the ability to eliminate cancer cells. MICHAEL: And can you maybe talk a little bit about how your approach and your solution are a little bit different from maybe what others are pursuing or what's currently available to patients? RUKIYAH: So current therapeutic agents are incredible. They're much more effective than agents that were available in the past. And so these remarkable agents have the ability to cure cancers in some settings. But the problem is, is that these amazing drugs are not effective in every patient. So what we want to do is to develop an agent that is effective against those resistant tumors, and so provide alternative therapies for people who are not responding to the current agents that are available. MICHAEL: Oh, that's really interesting. So are there specific types of melanoma that your research shows your drug is more effective against, whereas the current treatments aren't effective? RUKIYAH: Yes, our research thus far is showing that when we use a model, that is resistant to the current therapies, our drug can work in that resistant model. In addition, we're also finding that we can help the drugs that are already available to be even more effective. So we're looking at our drug as a single agent and also combined with other agents to see where is our niche, where does our drug work best? In addition, in our future studies, we plan to test other types of melanoma, those rare melanomas to which therapeutics that are currently available are not effective, so we can foresee using this agent in the treatment of different types of melanoma. MICHAEL: So that's really interesting. You're kind of pursuing both the single agent approach, where you would be the primary treatment for the melanoma, but you're also looking at combination therapies. I'm curious, are you collaborating with any other companies that are also in the same space? And does it look like your drug is complimentary to their drug? RUKIYAH: Yes, so that's one of our next steps. We're working to identify companies that we can work with in order to do that testing. And we plan to try to use both of those agents together, yes. MICHAEL: And so what stage are you, are you at now? Have you optimized your leads or are you into IND enabling studies? RUKIYAH: So right now we're in the stage, we're in the middle of doing our proof of concept studies. And our goal here is to find out the best way to administer the drug, under which circumstances. And we also want to identify the types of tumors to which our drug responds the most effectively. And so, we are now approaching the stage where we're going to begin a fundraising round. And with that fundraising, what we plan to do is to use those dollars in order to fund the regulatory studies that we need to prepare for that IND meeting. MICHAEL: Can you maybe talk a little bit about how you think your team is uniquely positioned to succeed in terms of developing the drug? And you know, it's a long path to get a drug from the very earliest stages, where you are, all the way into the clinic, treating patients, and then ultimately out to patients and getting FDA approval. How is your team uniquely positioned to succeed, do you feel? RUKIYAH: You know, our team is composed of individuals who are experts in their field. We are constantly evaluating and modifying our team to make sure that we have the expertise on board when we need it. And so I believe, though, that our special formula is that several members on our team have a personal cancer story, and that personal cancer story helps us to stay motivated, and it helps us to use that experience, plus our talents, to keep driving this process forward. And you know, most people have a cancer story. And you know, to be able to use that as your passion and your motivation, to make sure that you do your best to move it forward, is the unique part of our team because most of us do have that experience. MICHAEL: Yeah. No, I think you guys bring a really unique perspective with that. And I agree with you, as a cancer survivor, that does provide a very special motivation and a connection with cancer patients too. Rukiyah, maybe you could also talk a little bit about your, you know, your process for applying for your NCI SBIR award. You know, did you interact with an SBIR program director before you applied? And if you did, how did that help, help you out? RUKIYAH: So I submitted an application for the SBIR STTR several times before it was actually funded. And I will say that in the beginning, for my first couple of submissions, I did not interact with the program director. However, on the later stages, I began interacting with the program director. And one of the reasons that I didn't interact with the program director initially was that I kind of felt like it might be wasting their time. I didn't want to bother them, and I was concerned that if I asked the wrong question, it might appear that I was not ready for this opportunity. So I chose not to do it, but that was not really the best way to go, because as I mentioned in my later submissions, I started interacting with the program officers and I can tell you it made all of the difference in the world. The program directors, you are not wasting their time when you call them, set up an appointment, you're not wasting their time at all. And they're very friendly, they're very helpful, and I can tell you, I learned so much from interacting with them that it really made the difference in getting that application funded. And so, you know, in interacting with the program directors, they gave you, they'll give you lots of helpful information. You may ask a question and you may think that you know the answer to it, but there may be more to it, and they can give you more insight into, you know, why a particular situation may be important. They may open up some other opportunities that you were not aware of, so very, very helpful to interact with your program officers. And I can say, in my experience, I've had wonderful program officers, like Billy Bozza, who is wonderful. And I can tell you that the most important interaction that I had, as I mentioned, I submitted my application several times, and I was at the stage where I was going to give up and I wasn't going to resubmit again. And I can tell you that he told me “Don't give up. Let's try again, you’re this close. Let's try it again and see what happens.” And he gave me advice that I needed to, to really focus on those issues that the reviewers thought needed to be bolstered, and again, it made all of the difference in the world. So interacting with your program officers can make the difference between getting the application funded and not getting it funded, part of what they do is to help you to get your proposal funded. MICHAEL: Yeah. No, that's really valuable feedback. And we, we actually spend probably at least a third of our time interacting with, with applicants like yourself, because it can be a really, if you haven't applied for an SBIR grant at the NIH, you know, it can seem like a tall hill to climb sometimes, but our programs there, our program directors are there to help kind of smooth things over, explain the process, explain the different parts of the application, and really advise overall on what the NIH peer reviewers tend to look for in a strong proposal. So we actually think that's one of the most important parts of our jobs is interacting with applicants like yourself and others, and really trying to demystify the process and making it easier too. So it's really helpful to hear that back. Now, did you also participate in the Applicant Assistance Program and, and if so, how did that kind of change the way you approached the application process? RUKIYAH: Yes, I did participate in the Applicant Assistant Program and again, it was a great program. It really helped me to compose an application that was fundable. So I'll start by saying that both me and my institution have limited experience with the SBIR/STTR Grant. So because of this, I had no mentorship. I didn't really know how to put this grant together because it's very different from a traditional R grant. And so, without that mentorship, you know, I would compose it, submit it, and you know, that's how I would get my feedback as to how to put this together. So then by participating in the AAP, the people who are administering that program have extensive experience putting these types of grants together, and so they really helped me, provided me with the guidance that I need to put a fundable application together. So for example, they helped me to understand what was allowable in terms of a company budget. We know as academics what's allowable as, on the budget, but on the company side it's a little bit different, so they help me to bridge my understanding of the company and the academic setting so that the budget would be set up properly. Another example, they helped me with other aspects of the sheets of the different forms that needed to be filled out dealing with the company side of this whole process. And they also helped me to understand what are the expectations or the most likely expectations of the reviewers. Again, the reviewer board is composed not only of scientists, but people who are business people, and I have no formal business training, so that helped me a lot to really refocus and think about what is expected in that grant, and the people in the AAP program helped me to understand that. And so also another really important thing, as we were going through this process, the program will put you on a schedule. And so with that schedule, you have deadlines and milestones, and you complete these things on time so that the package is ready well in advance of the deadline, and this is really important because we all know when you wait till the last minute, it’s really difficult to put in a good package. And so by setting up those deadlines, it really helped me to be able to compose it and then to be able to come back and look at it later, with a fresh mind and fresh thoughts. And so the AAP program was really, really helpful and I highly recommend it. MICHAEL: That's -- I think that's really valuable feedback to our listeners today. We set up the AAP program about five years ago and it really is -- it was set up to do the exactly the things that you described, which is taking applicants, as they're putting together their, their applications, and really kind of coaching them, providing a coach who can kind of guide them through the whole application process. I've heard from a number of companies who have gone through AAP, like yourself, that it really did help them prepare to get an award. Sometimes they had applied in the past, like, like you had, and had not been successful. But then when they went through AAP and then they, they resubmitted their proposals and they learned, you know, from the coach who was kind of guiding them, they got stronger scores when they reapplied like you did, and then we were able to give them an award, because they had strengthened their application. So that that's the whole goal of the Applicant Assistance Program, and for those who are interested, we're actually going to be putting on a webinar on April the 25th, talking about the Applicant Assistance Program. And you can sign up and apply to participate in, in the AAP program. So April 25th is the next date for the webinar, I encourage folks to attend that. And you can also go to our website at sbir.cancer.gov and get more information about the Applicant Assistance Program there. OK, moving on just a little bit, you have a background that is very similar to what our, a lot of our applicants are experiencing when they're first getting involved in SBIR, and that you come from an academic background and you were working to start up your company, I'm sure there are a lot of challenges involved in that, because, you know, you're, you're an academic by training, you were not an entrepreneur. So you've had to kind of learn that along the way. So maybe it would, it would be really useful to our listeners, could you maybe talk a little bit about some of the key lessons learned as you've gone through your commercialization journey? And were there -- Was there any, any coursework, like, for example, the I-Corps program that you were able to tap into in order to give you the kind of information you needed to help as you were building your company? RUKIYAH: So yes, key lessons learned. I learned a lot of lessons in developing a company. As I mentioned, I have no formal business training, but what I did to kind of understand the basics of business is to attend lots of different workshops. Those workshops provided me with some information about business, about drug development. And then, what I started doing is to partner with people who are experts, so I don't have to be the business professional. But what my goal is, is to learn enough about business to understand with the business partners are talking about, and also to be able to contribute to the decision making process. And so that's my goal with learning about business, and I use the skills that we use as academics all the time and collaborate. Collaborate, bring people in who have the expertise that you need, rather than trying to be a professional or to be in a position that you really don't have the qualifications for. And so that's been my approach for making this happen. And so another thing that I've learned about business is that business is quite different from academia. In academia, we plan, we, we aim for perfection, and we have a route, and we try to stay with it and pivot when the science takes us there. In the business world, it’s a lot different. And I think the general mentality is that you are going to make mistakes. And so as, as was mentioned, you know business is new for me. So I've made mistakes and the idea is mistakes are expected. And when you make those mistakes, you just pick up and keep moving forward. The key is to have people around you who understand the business and know how to mitigate those mistakes and keep moving forward. MICHAEL: Yeah, I think those are, those are excellent lessons. There, there is a program, in addition to the valuable training that you were able to seek out in the -- and the mentors you were able to seek out on your own, NIH also offers a program called Innovation Corps or I-Corps, and it's open right now to companies that have an SBIR at the NIH, whether it's at NCI or a different institute. And it's really kind of like a boot camp to help companies learn how to put together a business strategy around the technology that they're developing. So it's a 10 week program we bring in instructors who are experts in areas like therapeutics, devices, diagnostics, and they are there to help guide the participants in going through that program. We have found that I-Corps has really helped launch a lot of our companies and really advanced through the development process. And it really does that through companies learning what the value proposition, and where their, where their technology can really make an impact and solve an unmet need. So I encourage folks to go up on our website and look for information about I-Corps program, I-C-O-R-P-S. RUKIYAH: So you're absolutely correct. The I-Corps is a wonderful program. I also participated in this program as well and it helped me to identify the specific niche of my product. So where does your product fit in this vast market of products that offer to do similar things? So I-Corps is really important to help you really fine tune your commercialization plan. And you know, I've also participated in other programs that I think are really, really important. For example, the SBIR-STTR workshops and road shows, man, those are some great programs. And I'll say that I've attended these programs over and over again because each time that I go or I participate, I learn something new. And it reminds you of all of the options that are available to really push your product forward. So it's a great idea to really attend these workshops and pick up as much knowledge as you can in order to push, push your technology forward. Also, once your grant is funded, I would like to recommend the Women's Innovation Network or WIN. That's a great program. It provides a supportive community of female SBIR-STTR recipients. It provides mentoring. We have speakers who talk about different aspects of commercialization, and it provides an opportunity for female investigators to network with each other, and to be a little vulnerable. And by being vulnerable, we can help each other, and so I recommend that as well. I'd also like to recommend, for those who are seeking to develop a business, a biotechnology business for their laboratory discoveries, you may have some local resources that you can tap into. Many states have different biotechnology professional organizations that put on workshops and they -- some provide funding. And they provide different types of education about entrepreneurship. So there may be some local organizations that you can also take part in, in order to learn, to build your business. And I would probably start to find out about if your state has a similar organization. Maybe start in your office of technology transfer, because that's the location where, in academia, that's kind of the line between academia and the commercial environment. So I would start there to find out if there are some local organizations that can also help you to get where you need to go. MICHAEL: Yeah. And really thanks so much for bringing some of these programs up. Rukiyah. One of the things that I like to talk about, when I talk about our SBIR program is, I think people understand that SBIR provides funding, which is obviously the most critical element. The way I like to think of it is it's necessary, obviously, but it's not sufficient. You know, you’re small business, you need funding obviously, but you need access to a whole range of different resources in addition to funding. So that's one of the things that separates the NCI SBIR program, I think, from others in that we really put a lot of time into thinking about and creating resource programs that our companies need. So just as an example, you mentioned I-Corps, that was one program we created here at NCI SBIR for the NIH as a whole. But we also offer our Investor Initiatives Program, too, where we are able to connect companies that we're funding through our SBIR program with private investors. So that, you know, as you're developing your drug, you're in the earlier stages now, you're obviously going to need to go out and raise additional capital. Because we're the NCI, we're able to develop relationships with some of the largest investors around the country, whether that's large pharmaceutical companies or some of the large venture capital funds around the country that invest in the cancer space. So once a year, we invite all the companies that we are funding in our portfolio to go through our Investor Initiatives Program. And that's an opportunity for you to put together a short application, which will then be reviewed by a panel of investors. And then those investors help us identify companies that are ready to go out and present and pitch their technology to, to other investors in order to help raise capital. And then we also do pitch coaching, to help, to help prepare our companies to, to go out and present. RUKIYAH: I can say that that's really important because in this current climate, it's very difficult to raise funds. So having that edge, having those connections would be very helpful. MICHAEL: I was wondering, maybe you could provide some advice. You mentioned the WIN Program as an example, you know, a program that we offer to women entrepreneurs in our program, and give them the opportunity to come together and really kind of share lessons learned. In addition to that, do you have any other advice for women in academia who want to transfer their technology and really kind of start that journey towards a start up? RUKIYAH: Sure. You know, the first thing that I would say is that this is very doable. It's doable because women have some ingrained properties that are really conducive to making this happen. For example, our ability to multitask is very important and very critical for getting this job done. And so the job of transferring the technology into the commercial space takes a lot of multitasking. You can work with different people in order to get things done. Collaboration, that's also another property that we have as academics, and so we can collaborate with people in order to get things done. And so for me personally, one of the things that I had to resist was the urge to be Superwoman. And so for me, what I usually try to do is do everything myself and, you know, try to achieve it all by myself, and that's really not the way to go. What you - What is successful is to collaborate and delegate in order to achieve your goals. So that's one of the things that I would say that we really have to do as women, collaborate, don't try to do it all, find the experts and let the experts do what they know how to do. And then finally, I would say in terms of advice for women, I would say ask for what you want. Sometimes we don't like to ask and -- ask people for help or ask for resources, but you have to ask, all, all that can be said is either yes or no. So just ask and if the answer is no, try another route and keep moving forward. Don't take it personally, just keep moving forward. MICHAEL: I really think that's -- I think -- I really think that's excellent advice. There's, there's another program really focusing on academics doing the research, developing a technology who are interested in making that transition. There's another program that we offer called the Small Business Transition Grant. It's a fairly new program, not a lot of folks are, are aware of it, but we're really trying to, to increase the awareness of that program and that, that program, we actually developed in response to conversations we were having with our cancer centers from across the country, where we were trying to figure out what can the NCI do to facilitate the translation of academic technologies and to get more technologies out of the lab and into small companies. And one of the key funding gaps that they told us was existing, was that it was really hard for early career academics, like post-docs, to raise funds. You know, there was kind of a dearth of funding when, when you're really at the early stages in your career trying to raise funding. So the Small Business Transition Grant actually is focused on, on post-docs and other early career academics, and it will provide funding to them while they're still at the university, both for their research as well as funding for both a technical mentor and a business mentor. And the whole goal is to provide kind of the, the support that that early-career academic needs, you know, sounds -- and it sounds like you were kind of in that same situation, but the goal is to provide funding as well as mentorship support to that early-career academic to help them as they're looking to move their technology out of a university to a small business. You can apply for either just a Phase 1 application or you can go for a combined Phase 1/Phase 2 application. And the funding will support the academic, first at the university, and then as they move their technology to a company, and they move -- and they advance that technology to a Phase 2, it'll continue that same support. So, it's another program that we have tried to tailor to the needs of you and other academics that are out there looking to apply. And, again, we have information about the Small Business Transition Grant up on our website at sbir.cancer.gov. We're actually going to be launching that program for the coming year sometime in, in March. So if you're interested in that, and I encourage everyone to, again, go up on our website to get more information and talk to a program director, reach out to us, send us an e-mail, and we're happy to give you more information about that program. RUKIYAH: Sounds like a really interesting project. I think it's a great idea because young -- Generation Z, Young investigators, they want to own businesses, a very different mentality from previous generations. So this type of program sounds like it would be really great to help to launch their ideas and their businesses in the biotech space. MICHAEL: Absolutely. And that's what we're trying to do with that, that program right now. It's, again, it's still a fairly young program, so we're, we're trying to, we're trying to talk about it a little bit more with folks like yourself to just kind of raise visibility that that's, that's a funding opportunity that an academic who's interested in moving to a small business, maybe creating their own small business, it's a funding opportunity that's, that's available to help to, to help support them on that. Well, this has been great. I've really enjoyed our conversation. I wanted to ask you just one last question, and that's, is there one piece of advice that you'd like to leave folks with before we leave today regarding, you know, your journey or their journey as they're looking to start it? RUKIYAH: Sure. I would say the best piece of advice that I can give is to use your skills that you have acquired as an academic researcher to start and grow your company. The skills that are necessary to make this work include: collaboration, persistence. You have to be persistent, networking. And so you can also use your passion, what is it that you really feel passionate about in order to keep the process moving forward? And then I would also advise you to take advantage of the resources that are available to help you with commercialization of biotechnology products. I would also say, as you mentioned, this is a very long drawn out process. So I would advise you to know what the process is, but don't focus on the big picture, focus on your milestones, because if you get focused on how big this whole process is, it's discouraging, right, and it may prevent you from moving forward. So just break your process up into milestones, achieve your next milestone, and, and view it from that perspective, rather than being focused on all that needs to be done. And I think that that has been really helpful to me to just kind of take this at small pieces. MICHAEL: Excellent advice, break it down step-by-step and if you can work on it step-by-step, then it's not such an overwhelming kind of thing, you know, set your goals, achieve that one goal, and move to the next one. Well, this has been wonderful. I've really enjoyed our conversation today. Thank you for taking the time. And I know it's going to be really valuable to a lot of the folks out in the community who are interested in coming back and applying for NCI SBIR. We look forward to working together with you in the future. And again, thank you. RUKIYAH: Thank you so much for inviting me to talk. I hope that some of the information that I've shared will be helpful to someone. And it is great to be part of a community of people who are really devoted to developing cancer chemotherapeutics. And again, I just thank you for the invitation. MICHAEL: Thank you. Thanks so much Rukiyah for speaking with us today. We really look forward to seeing Claradele’s continued growth and making positive patient impact. As always, don't forget to check out our website, sbir.cancer.gov, for the latest funding opportunities and commercialization resources to support your journey from lab to market. This was Michael Weingarten from NCI SBIR. Please join us again for the next installment of NCI SBIR Innovation Lab and subscribe today wherever you listen. If you have questions about cancer or comments about this podcast, e-mail us at nciinfo@nih.gov or call us at 1-800-422-6237 and please be sure to mention Innovation Lab in your query. We are a production of the US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Thanks so much for listening. [music] END OF FILE "/><meta name="google" content="notranslate"/><meta name="music:duration" content="2373"/><meta name="music:album" content="https://open.spotify.com/show/4ZgsJahci1QqCScnHHZjEZ"/><meta name="music:release_date" content="2024-03-20T08:00:00Z"/><meta name="al:android:app_name" content="Spotify"/><meta name="al:android:package" content="com.spotify.music"/><meta name="al:android:url" content="spotify://episode/0BUwq1DLQg9KAFG1jaV4mC"/><meta name="al:ios:app_name" content="Spotify"/><meta name="al:ios:app_store_id" content="324684580"/><meta name="al:ios:url" content="spotify://episode/0BUwq1DLQg9KAFG1jaV4mC"/><meta property="og:title" content="Episode 6. Entrepreneur Spotlight: Rukiyah Van Dross-Anderson, Claradele Pharmaceuticals"/><meta property="og:description" content="SBIR Innovation Lab · Episode"/><meta property="og:url" content="https://open.spotify.com/episode/0BUwq1DLQg9KAFG1jaV4mC"/><meta property="og:type" content="music.song"/><meta property="og:site_name" content="Spotify"/><meta property="og:restrictions:country:allowed" content="AD"/><meta property="og:restrictions:country:allowed" content="AE"/><meta property="og:restrictions:country:allowed" content="AG"/><meta property="og:restrictions:country:allowed" content="AL"/><meta property="og:restrictions:country:allowed" content="AM"/><meta property="og:restrictions:country:allowed" content="AO"/><meta property="og:restrictions:country:allowed" content="AR"/><meta property="og:restrictions:country:allowed" content="AT"/><meta property="og:restrictions:country:allowed" content="AU"/><meta property="og:restrictions:country:allowed" content="AZ"/><meta property="og:restrictions:country:allowed" content="BA"/><meta property="og:restrictions:country:allowed" content="BB"/><meta property="og:restrictions:country:allowed" content="BE"/><meta property="og:restrictions:country:allowed" content="BF"/><meta property="og:restrictions:country:allowed" content="BG"/><meta property="og:restrictions:country:allowed" content="BH"/><meta property="og:restrictions:country:allowed" content="BI"/><meta property="og:restrictions:country:allowed" content="BJ"/><meta property="og:restrictions:country:allowed" content="BN"/><meta property="og:restrictions:country:allowed" content="BO"/><meta property="og:restrictions:country:allowed" content="BR"/><meta property="og:restrictions:country:allowed" content="BS"/><meta property="og:restrictions:country:allowed" content="BT"/><meta property="og:restrictions:country:allowed" content="BW"/><meta property="og:restrictions:country:allowed" content="BZ"/><meta property="og:restrictions:country:allowed" content="CA"/><meta property="og:restrictions:country:allowed" content="CH"/><meta property="og:restrictions:country:allowed" content="CI"/><meta property="og:restrictions:country:allowed" content="CL"/><meta property="og:restrictions:country:allowed" content="CM"/><meta property="og:restrictions:country:allowed" content="CO"/><meta property="og:restrictions:country:allowed" content="CR"/><meta property="og:restrictions:country:allowed" content="CV"/><meta property="og:restrictions:country:allowed" content="CW"/><meta property="og:restrictions:country:allowed" content="CY"/><meta property="og:restrictions:country:allowed" content="CZ"/><meta property="og:restrictions:country:allowed" content="DE"/><meta property="og:restrictions:country:allowed" content="DJ"/><meta property="og:restrictions:country:allowed" content="DK"/><meta property="og:restrictions:country:allowed" content="DM"/><meta property="og:restrictions:country:allowed" content="DO"/><meta property="og:restrictions:country:allowed" content="DZ"/><meta property="og:restrictions:country:allowed" content="EC"/><meta property="og:restrictions:country:allowed" content="EE"/><meta property="og:restrictions:country:allowed" content="EG"/><meta property="og:restrictions:country:allowed" content="ES"/><meta property="og:restrictions:country:allowed" content="FI"/><meta property="og:restrictions:country:allowed" content="FJ"/><meta property="og:restrictions:country:allowed" content="FM"/><meta property="og:restrictions:country:allowed" content="FR"/><meta property="og:restrictions:country:allowed" content="GA"/><meta property="og:restrictions:country:allowed" content="GB"/><meta property="og:restrictions:country:allowed" content="GD"/><meta property="og:restrictions:country:allowed" content="GE"/><meta property="og:restrictions:country:allowed" content="GH"/><meta property="og:restrictions:country:allowed" content="GM"/><meta property="og:restrictions:country:allowed" content="GN"/><meta property="og:restrictions:country:allowed" content="GQ"/><meta property="og:restrictions:country:allowed" content="GR"/><meta property="og:restrictions:country:allowed" content="GT"/><meta property="og:restrictions:country:allowed" content="GW"/><meta property="og:restrictions:country:allowed" content="GY"/><meta property="og:restrictions:country:allowed" content="HK"/><meta property="og:restrictions:country:allowed" content="HN"/><meta property="og:restrictions:country:allowed" content="HR"/><meta property="og:restrictions:country:allowed" content="HT"/><meta property="og:restrictions:country:allowed" content="HU"/><meta property="og:restrictions:country:allowed" content="ID"/><meta property="og:restrictions:country:allowed" content="IE"/><meta property="og:restrictions:country:allowed" content="IL"/><meta property="og:restrictions:country:allowed" content="IN"/><meta property="og:restrictions:country:allowed" content="IS"/><meta property="og:restrictions:country:allowed" content="IT"/><meta property="og:restrictions:country:allowed" content="JM"/><meta property="og:restrictions:country:allowed" content="JO"/><meta property="og:restrictions:country:allowed" content="JP"/><meta property="og:restrictions:country:allowed" content="KE"/><meta property="og:restrictions:country:allowed" content="KH"/><meta property="og:restrictions:country:allowed" content="KI"/><meta property="og:restrictions:country:allowed" content="KM"/><meta property="og:restrictions:country:allowed" content="KN"/><meta property="og:restrictions:country:allowed" content="KR"/><meta property="og:restrictions:country:allowed" content="KW"/><meta property="og:restrictions:country:allowed" content="LA"/><meta property="og:restrictions:country:allowed" content="LB"/><meta property="og:restrictions:country:allowed" content="LC"/><meta property="og:restrictions:country:allowed" content="LI"/><meta property="og:restrictions:country:allowed" content="LR"/><meta property="og:restrictions:country:allowed" content="LS"/><meta property="og:restrictions:country:allowed" content="LT"/><meta property="og:restrictions:country:allowed" content="LU"/><meta property="og:restrictions:country:allowed" content="LV"/><meta property="og:restrictions:country:allowed" content="MA"/><meta property="og:restrictions:country:allowed" content="MC"/><meta property="og:restrictions:country:allowed" content="ME"/><meta property="og:restrictions:country:allowed" content="MG"/><meta property="og:restrictions:country:allowed" content="MH"/><meta property="og:restrictions:country:allowed" content="MK"/><meta property="og:restrictions:country:allowed" content="ML"/><meta property="og:restrictions:country:allowed" content="MN"/><meta property="og:restrictions:country:allowed" content="MO"/><meta property="og:restrictions:country:allowed" content="MR"/><meta property="og:restrictions:country:allowed" content="MT"/><meta property="og:restrictions:country:allowed" content="MU"/><meta property="og:restrictions:country:allowed" content="MV"/><meta property="og:restrictions:country:allowed" content="MW"/><meta property="og:restrictions:country:allowed" content="MX"/><meta property="og:restrictions:country:allowed" content="MY"/><meta property="og:restrictions:country:allowed" content="MZ"/><meta property="og:restrictions:country:allowed" content="NA"/><meta property="og:restrictions:country:allowed" content="NE"/><meta property="og:restrictions:country:allowed" content="NG"/><meta property="og:restrictions:country:allowed" content="NI"/><meta property="og:restrictions:country:allowed" content="NL"/><meta property="og:restrictions:country:allowed" content="NO"/><meta property="og:restrictions:country:allowed" content="NP"/><meta property="og:restrictions:country:allowed" content="NR"/><meta property="og:restrictions:country:allowed" content="NZ"/><meta property="og:restrictions:country:allowed" content="OM"/><meta property="og:restrictions:country:allowed" content="PA"/><meta property="og:restrictions:country:allowed" content="PE"/><meta property="og:restrictions:country:allowed" content="PG"/><meta property="og:restrictions:country:allowed" content="PH"/><meta property="og:restrictions:country:allowed" content="PL"/><meta property="og:restrictions:country:allowed" content="PR"/><meta property="og:restrictions:country:allowed" content="PS"/><meta property="og:restrictions:country:allowed" content="PT"/><meta property="og:restrictions:country:allowed" content="PW"/><meta property="og:restrictions:country:allowed" content="PY"/><meta property="og:restrictions:country:allowed" content="QA"/><meta property="og:restrictions:country:allowed" content="RO"/><meta property="og:restrictions:country:allowed" content="RS"/><meta property="og:restrictions:country:allowed" content="RW"/><meta property="og:restrictions:country:allowed" content="SA"/><meta property="og:restrictions:country:allowed" content="SB"/><meta property="og:restrictions:country:allowed" content="SC"/><meta property="og:restrictions:country:allowed" content="SE"/><meta property="og:restrictions:country:allowed" content="SG"/><meta property="og:restrictions:country:allowed" content="SI"/><meta property="og:restrictions:country:allowed" content="SK"/><meta property="og:restrictions:country:allowed" content="SL"/><meta property="og:restrictions:country:allowed" content="SM"/><meta property="og:restrictions:country:allowed" content="SN"/><meta property="og:restrictions:country:allowed" content="SR"/><meta property="og:restrictions:country:allowed" content="ST"/><meta property="og:restrictions:country:allowed" content="SV"/><meta property="og:restrictions:country:allowed" content="SZ"/><meta property="og:restrictions:country:allowed" content="TD"/><meta property="og:restrictions:country:allowed" content="TG"/><meta property="og:restrictions:country:allowed" content="TH"/><meta property="og:restrictions:country:allowed" content="TL"/><meta property="og:restrictions:country:allowed" content="TN"/><meta property="og:restrictions:country:allowed" content="TO"/><meta property="og:restrictions:country:allowed" content="TR"/><meta property="og:restrictions:country:allowed" content="TT"/><meta property="og:restrictions:country:allowed" content="TV"/><meta property="og:restrictions:country:allowed" content="TW"/><meta property="og:restrictions:country:allowed" content="TZ"/><meta property="og:restrictions:country:allowed" content="UA"/><meta property="og:restrictions:country:allowed" content="US"/><meta property="og:restrictions:country:allowed" content="UY"/><meta property="og:restrictions:country:allowed" content="UZ"/><meta property="og:restrictions:country:allowed" content="VC"/><meta property="og:restrictions:country:allowed" content="VN"/><meta property="og:restrictions:country:allowed" content="VU"/><meta property="og:restrictions:country:allowed" content="WS"/><meta property="og:restrictions:country:allowed" content="XK"/><meta property="og:restrictions:country:allowed" content="ZA"/><meta property="og:restrictions:country:allowed" content="ZM"/><meta property="og:restrictions:country:allowed" content="ZW"/><meta property="og:audio" content="https://podz-content.spotifycdn.com/audio/clips/18Nn6VFMnXRGgN3BVvSQVa/clip_428102_488102.mp3"/><meta property="og:audio:type" content="audio/mpeg"/><meta property="og:image" content="https://i.scdn.co/image/ab6765630000ba8a47af993b6b750468dbd95041"/><meta name="twitter:site" content="@spotify"/><meta name="twitter:title" content="Episode 6. Entrepreneur Spotlight: Rukiyah Van Dross-Anderson, Claradele Pharmaceuticals"/><meta name="twitter:description" content="SBIR Innovation Lab · Episode"/><meta name="twitter:image" content="https://i.scdn.co/image/ab6765630000ba8a47af993b6b750468dbd95041"/><meta name="twitter:card" content="summary"/><link rel="canonical" href="https://open.spotify.com/episode/0BUwq1DLQg9KAFG1jaV4mC"/><link rel="alternate" type="application/json+oembed" href="https://open.spotify.com/oembed?url=https%3A%2F%2Fopen.spotify.com%2Fepisode%2F0BUwq1DLQg9KAFG1jaV4mC"/><link rel="alternate" href="https://open.spotify.com/episode/0BUwq1DLQg9KAFG1jaV4mC" hrefLang="x-default"/><link rel="alternate" href="https://open.spotify.com/episode/0BUwq1DLQg9KAFG1jaV4mC" hrefLang="en"/><link rel="alternate" href="android-app://com.spotify.music/spotify/episode/0BUwq1DLQg9KAFG1jaV4mC"/><script type="application/ld+json">{"@context":"http://schema.googleapis.com/","@type":"MusicGroup","@id":"https://open.spotify.com/episode/0BUwq1DLQg9KAFG1jaV4mC","url":"https://open.spotify.com/episode/0BUwq1DLQg9KAFG1jaV4mC","name":"Episode 6. Entrepreneur Spotlight: Rukiyah Van Dross-Anderson, Claradele Pharmaceuticals","description":"Listen to this episode from SBIR Innovation Lab on Spotify. NCI SBIR Director Michael Weingarten and Rukiyah Van Dross-Anderson, Founder and CEO of SBIR-funded Claradele Pharmaceuticals discuss the journey from postdoc to biotech startup and how women and underrepresented entrepreneurs with innovative cancer solutions can also leverage SBIR support to move their ideas forward. Listen to this podcast to hear: \u2022\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 Stages of product development (fundraising rounds, company collaborations, team culture development, and more) \u2022\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 Lessons Learned when transitioning from academia to the early stages of product commercialization \u2022\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 Benefits of contacting program directors when applying for SBIR/STTR opportunities \u2022\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 Coaching received through the Applicant Assistance Program \u2022\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 Utilizing state biotech professional organizations \u2022\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 Programs early-stage businesses can use \u00A0 Podcast Guest Speakers: Name Bios Michael Weingarten, MA Director SBIR Development Center National Cancer Institute \u00A0 In this role, Michael Weingarten leads a team of nine Program Directors who manage all aspects of the NCI SBIR & STTR Programs including a portfolio of $182M in grants and contracts annually. The SBIR & STTR programs are NCI's engine of innovation for developing and commercializing novel technologies and products to prevent, diagnose, and treat cancer. Weingarten has implemented a set of key initiatives for optimizing the performance of the NCI SBIR Program at the NIH. These include the establishment of a new model at the NCI for managing the program - the SBIR Development Center.\u00A0 \u00A0 \u00A0 Rukiyah Van Dross-Anderson, PhD Founder and CEO Claradele Pharmaceuticals \u00A0 Rukiyah T. Van Dross-Anderson, PhD is the CEO and founder of NCI SBIR-funded therapeutics company, Claradele Pharmaceuticals. Her work began at East Carolina University, where she is an associate professor and the director of Graduate Programs, Pharmacology & Toxicology Concentration. Dr. Van Dross-Anderson is working to develop an effective and non-toxic drug as an alternative therapeutic regimen for melanoma patients who aren\u2019t responsive to traditional treatments.\u00A0 To attract third-party investors that would help get her innovation to get to the patients that need them, Dr. Van Dross-Anderson is working through proof-of-concept studies to demonstrate her innovation\u2019s commercial viability. Through her participation in the NCI SBIR program, she used funding to scale up production and received entrepreneurial mentorship to navigate the complex business world. Dr. Van Dross-Anderson graduated from Rutgers University, UMDNJ-RWJMS with a doctoral degree in Molecular and Cellular Pharmacology. \u00A0 Programs referenced in this episode: \u2022\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 Minority Biomedical Research Symposium (MBRS) program - http://mbrs.newark.rutgers.edu/ \u2022\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 Minority Access to Research Careers - https://www.nigms.nih.gov/training/MARC/Pages/USTARAwards.aspx \u2022\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 Applicant Assistance Program - https://sbir.cancer.gov/small-business-funding/application-process/applicant-assistance \u2022\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 I-Corps at NIH program - https://sbir.cancer.gov/commercialization/business/icorps \u2022\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 NCI SBIR Women\u2019s Innovation Network \u2022\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 Office of technology transfer (offered at most school) \u2022\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 NCI SBIR Investor Initiative - https://sbir.cancer.gov/commercialization/business/investor-initiatives \u2022\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 Small Business Transition Grant - https://sbir.cancer.gov/small-business-funding/grants/small-business-transition Transcript: \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 KEY:\u00A0\u00A0\u00A0\u00A0 MICHAEL = Michael Weingarten, \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0RUKIYAH = Dr. Rukiyah Van Dross-Anderson \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 [music] \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 MICHAEL: Hello and welcome to Innovation Lab, your go to resource for all things biotech startups, brought to you by the National Cancer Institute\u2019s Small Business Innovation Research, SBIR Development Center. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 Our podcast hosts interviews with successful entrepreneurs and provides resources for small businesses looking to take their cutting edge cancer solutions from lab to market. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 I'm Michael Weingarten, the director of NCI SBIR and today's host. Today, in celebration of the Women's History Month, I'm excited to introduce our listeners to one of our women awardees, Dr. Rukiyah Van Dross-Anderson. Rukiyah is the CEO and founder of an NCI SBIR funded therapeutics company Claradele Pharmaceuticals. Her work began at East Carolina University where she is an associate professor and the Director of Graduate Programs, Pharmacology and Toxicology Concentration. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 Dr. Van Dross-Anderson is working to develop an effective and non-toxic drug as an alternative therapeutic regimen for melanoma patients who aren't responsive to traditional treatments. We will discuss her journey from post-doc to biotech startup, and share how women and underrepresented entrepreneurs with innovative cancer solutions can also leverage SBIR support to move their ideas forward. Welcome, Rukiyah. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 RUKIYAH: Thank you. Thank you for having me. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 MICHAEL: Can you kind of walk us through the arc of your career and how your company Claradele was formed? \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 RUKIYAH: Oh, sure. So my research career began at Alabama State University, where I was a chemistry major, and through the university, I participated in some really important programs that helped me to understand that I really love research. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 So as an undergraduate, I was in the MBRS program, which stands for a Minority Biomedical Research Symposium. I was also a MARC student, Minority Access to Research Careers, and these two programs were NIH-funded programs that gave undergraduate students an opportunity to experience research. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 And it's through that experience that I found my true love, which is research. So after graduation from my undergraduate institution, I did two post-docs, one at Vanderbilt University and the other at the University of Kansas Medical Center. It was there that I honed my skills and really learned how to become a cancer researcher. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 From there I became part of the faculty at East Carolina University as an assistant professor, and I'm now an associate professor. And so throughout these years, I was really focused on developing novel agents that were effective against cancer. And so through this process, we discovered a novel molecule which we obtained a patent for to use as a therapeutic for melanoma and other types of cancer. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 And so thereafter the question was, what do we do next? What do we do with this molecule that we've patented and how do we get it to the stage where the public has access to it or the public can use this therapeutic? And so to kind of answer that question, I started attending different workshops that discuss the different options or the different ways in which drugs can be commercialized. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 And through this experience, I chose to form my biotech company, which is called Claradele Pharmaceuticals, and this company was founded in 2020. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 MICHAEL: Got it. So you've really had an interesting journey. You know, based on the research and then deciding to start Claradele. Can you maybe tell us a little bit more about the product and the technology that you've been working on, with funding that we've been providing from NCI SBIR? \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 RUKIYAH: Sure. Yeah. So what we're working on is developing a small molecule therapeutic. And this agent has the ability to kill melanoma cancer cells and also stimulate the immune system. So the action of cancer killing and stimulating the immune system are really critical for effective tumor eradication. \u00A0 \u00A0 \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 And our data, thus far, indicates that we have an agent with unique and promising properties that has the ability to eliminate cancer cells. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 MICHAEL: And can you maybe talk a little bit about how your approach and your solution are a little bit different from maybe what others are pursuing or what's currently available to patients? \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 RUKIYAH: So current therapeutic agents are incredible. They're much more effective than agents that were available in the past. And so these remarkable agents have the ability to cure cancers in some settings. But the problem is, is that these amazing drugs are not effective in every patient. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 So what we want to do is to develop an agent that is effective against those resistant tumors, and so provide alternative therapies for people who are not responding to the current agents that are available. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 MICHAEL: Oh, that's really interesting. So are there specific types of melanoma that your research shows your drug is more effective against, whereas the current treatments aren't effective? \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 RUKIYAH: Yes, our research thus far is showing that when we use a model, that is resistant to the current therapies, our drug can work in that resistant model. In addition, we're also finding that we can help the drugs that are already available to be even more effective. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 So we're looking at our drug as a single agent and also combined with other agents to see where is our niche, where does our drug work best? \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 In addition, in our future studies, we plan to test other types of melanoma, those rare melanomas to which therapeutics that are currently available are not effective, so we can foresee using this agent in the treatment of different types of melanoma. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 MICHAEL: So that's really interesting. You're kind of pursuing both the single agent approach, where you would be the primary treatment for the melanoma, but you're also looking at combination therapies. I'm curious, are you collaborating with any other companies that are also in the same space? And does it look like your drug is complimentary to their drug? \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 RUKIYAH: Yes, so that's one of our next steps. We're working to identify companies that we can work with in order to do that testing. And we plan to try to use both of those agents together, yes. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 MICHAEL: And so what stage are you, are you at now? Have you optimized your leads or are you into IND enabling studies? \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 RUKIYAH: So right now we're in the stage, we're in the middle of doing our proof of concept studies. And our goal here is to find out the best way to administer the drug, under which circumstances. And we also want to identify the types of tumors to which our drug responds the most effectively. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 And so, we are now approaching the stage where we're going to begin a fundraising round. And with that fundraising, what we plan to do is to use those dollars in order to fund the regulatory studies that we need to prepare for that IND meeting. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 MICHAEL: Can you maybe talk a little bit about how you think your team is uniquely positioned to succeed in terms of developing the drug? And you know, it's a long path to get a drug from the very earliest stages, where you are, all the way into the clinic, treating patients, and then ultimately out to patients and getting FDA approval. How is your team uniquely positioned to succeed, do you feel? \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 RUKIYAH: You know, our team is composed of individuals who are experts in their field. We are constantly evaluating and modifying our team to make sure that we have the expertise on board when we need it. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 And so I believe, though, that our special formula is that several members on our team have a personal cancer story, and that personal cancer story helps us to stay motivated, and it helps us to use that experience, plus our talents, to keep driving this process forward. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 And you know, most people have a cancer story. And you know, to be able to use that as your passion and your motivation, to make sure that you do your best to move it forward, is the unique part of our team because most of us do have that experience. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 MICHAEL: Yeah. No, I think you guys bring a really unique perspective with that. And I agree with you, as a cancer survivor, that does provide a very special motivation and a connection with cancer patients too. Rukiyah, maybe you could also talk a little bit about your, you know, your process for applying for your NCI SBIR award. You know, did you interact with an SBIR program director before you applied? And if you did, how did that help, help you out? \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 RUKIYAH: So I submitted an application for the SBIR STTR several times before it was actually funded. And I will say that in the beginning, for my first couple of submissions, I did not interact with the program director. However, on the later stages, I began interacting with the program director. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 And one of the reasons that I didn't interact with the program director initially was that I kind of felt like it might be wasting their time. I didn't want to bother them, and I was concerned that if I asked the wrong question, it might appear that I was not ready for this opportunity. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 So I chose not to do it, but that was not really the best way to go, because as I mentioned in my later submissions, I started interacting with the program officers and I can tell you it made all of the difference in the world. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 The program directors, you are not wasting their time when you call them, set up an appointment, you're not wasting their time at all. And they're very friendly, they're very helpful, and I can tell you, I learned so much from interacting with them that it really made the difference in getting that application funded. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 And so, you know, in interacting with the program directors, they gave you, they'll give you lots of helpful information. You may ask a question and you may think that you know the answer to it, but there may be more to it, and they can give you more insight into, you know, why a particular situation may be important. They may open up some other opportunities that you were not aware of, so very, very helpful to interact with your program officers. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 And I can say, in my experience, I've had wonderful program officers, like Billy Bozza, who is wonderful. And I can tell you that the most important interaction that I had, as I mentioned, I submitted my application several times, and I was at the stage where I was going to give up and I wasn't going to resubmit again. And I can tell you that he told me \u201CDon't give up. Let's try again, you\u2019re this close. Let's try it again and see what happens.\u201D \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 And he gave me advice that I needed to, to really focus on those issues that the reviewers thought needed to be bolstered, and again, it made all of the difference in the world. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 So interacting with your program officers can make the difference between getting the application funded and not getting it funded, part of what they do is to help you to get your proposal funded. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 MICHAEL: Yeah. No, that's really valuable feedback. And we, we actually spend probably at least a third of our time interacting with, with applicants like yourself, because it can be a really, if you haven't applied for an SBIR grant at the NIH, you know, it can seem like a tall hill to climb sometimes, but our programs there, our program directors are there to help kind of smooth things over, explain the process, explain the different parts of the application, and really advise overall on what the NIH peer reviewers tend to look for in a strong proposal. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 So we actually think that's one of the most important parts of our jobs is interacting with applicants like yourself and others, and really trying to demystify the process and making it easier too. So it's really helpful to hear that back. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 Now, did you also participate in the Applicant Assistance Program and, and if so, how did that kind of change the way you approached the application process? \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 RUKIYAH: Yes, I did participate in the Applicant Assistant Program and again, it was a great program. It really helped me to compose an application that was fundable. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 So I'll start by saying that both me and my institution have limited experience with the SBIR/STTR Grant. So because of this, I had no mentorship. I didn't really know how to put this grant together because it's very different from a traditional R grant. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 And so, without that mentorship, you know, I would compose it, submit it, and you know, that's how I would get my feedback as to how to put this together. So then by participating in the AAP, the people who are administering that program have extensive experience putting these types of grants together, and so they really helped me, provided me with the guidance that I need to put a fundable application together. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 So for example, they helped me to understand what was allowable in terms of a company budget. We know as academics what's allowable as, on the budget, but on the company side it's a little bit different, so they help me to bridge my understanding of the company and the academic setting so that the budget would be set up properly. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 Another example, they helped me with other aspects of the sheets of the different forms that needed to be filled out dealing with the company side of this whole process. And they also helped me to understand what are the expectations or the most likely expectations of the reviewers. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 Again, the reviewer board is composed not only of scientists, but people who are business people, and I have no formal business training, so that helped me a lot to really refocus and think about what is expected in that grant, and the people in the AAP program helped me to understand that. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 And so also another really important thing, as we were going through this process, the program will put you on a schedule. And so with that schedule, you have deadlines and milestones, and you complete these things on time so that the package is ready well in advance of the deadline, and this is really important because we all know when you wait till the last minute, it\u2019s really difficult to put in a good package. \u00A0 \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 And so by setting up those deadlines, it really helped me to be able to compose it and then to be able to come back and look at it later, with a fresh mind and fresh thoughts. And so the AAP program was really, really helpful and I highly recommend it. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 MICHAEL: That's -- I think that's really valuable feedback to our listeners today. We set up the AAP program about five years ago and it really is -- it was set up to do the exactly the things that you described, which is taking applicants, as they're putting together their, their applications, and really kind of coaching them, providing a coach who can kind of guide them through the whole application process. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 I've heard from a number of companies who have gone through AAP, like yourself, that it really did help them prepare to get an award. Sometimes they had applied in the past, like, like you had, and had not been successful. But then when they went through AAP and then they, they resubmitted their proposals and they learned, you know, from the coach who was kind of guiding them, they got stronger scores when they reapplied like you did, and then we were able to give them an award, because they had strengthened their application. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 So that that's the whole goal of the Applicant Assistance Program, and for those who are interested, we're actually going to be putting on a webinar on April the 25th, talking about the Applicant Assistance Program. And you can sign up and apply to participate in, in the AAP program. So April 25th is the next date for the webinar, I encourage folks to attend that. And you can also go to our website at sbir.cancer.gov and get more information about the Applicant Assistance Program there. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 OK, moving on just a little bit, you have a background that is very similar to what our, a lot of our applicants are experiencing when they're first getting involved in SBIR, and that you come from an academic background and you were working to start up your company, I'm sure there are a lot of challenges involved in that, because, you know, you're, you're an academic by training, you were not an entrepreneur. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 So you've had to kind of learn that along the way. So maybe it would, it would be really useful to our listeners, could you maybe talk a little bit about some of the key lessons learned as you've gone through your commercialization journey? And were there -- Was there any, any coursework, like, for example, the I-Corps program that you were able to tap into in order to give you the kind of information you needed to help as you were building your company? \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 RUKIYAH: So yes, key lessons learned. I learned a lot of lessons in developing a company. As I mentioned, I have no formal business training, but what I did to kind of understand the basics of business is to attend lots of different workshops. Those workshops provided me with some information about business, about drug development. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 And then, what I started doing is to partner with people who are experts, so I don't have to be the business professional. But what my goal is, is to learn enough about business to understand with the business partners are talking about, and also to be able to contribute to the decision making process. \u00A0 \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 And so that's my goal with learning about business, and I use the skills that we use as academics all the time and collaborate. Collaborate, bring people in who have the expertise that you need, rather than trying to be a professional or to be in a position that you really don't have the qualifications for. And so that's been my approach for making this happen. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 And so another thing that I've learned about business is that business is quite different from academia. In academia, we plan, we, we aim for perfection, and we have a route, and we try to stay with it and pivot when the science takes us there. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 In the business world, it\u2019s a lot different. And I think the general mentality is that you are going to make mistakes. And so as, as was mentioned, you know business is new for me. So I've made mistakes and the idea is mistakes are expected. And when you make those mistakes, you just pick up and keep moving forward. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 The key is to have people around you who understand the business and know how to mitigate those mistakes and keep moving forward. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 MICHAEL: Yeah, I think those are, those are excellent lessons. There, there is a program, in addition to the valuable training that you were able to seek out in the -- and the mentors you were able to seek out on your own, NIH also offers a program called Innovation Corps or I-Corps, and it's open right now to companies that have an SBIR at the NIH, whether it's at NCI or a different institute. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 And it's really kind of like a boot camp to help companies learn how to put together a business strategy around the technology that they're developing. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 So it's a 10 week program we bring in instructors who are experts in areas like therapeutics, devices, diagnostics, and they are there to help guide the participants in going through that program. We have found that I-Corps has really helped launch a lot of our companies and really advanced through the development process. And it really does that through companies learning what the value proposition, and where their, where their technology can really make an impact and solve an unmet need. So I encourage folks to go up on our website and look for information about I-Corps program, I-C-O-R-P-S. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 RUKIYAH: So you're absolutely correct. The I-Corps is a wonderful program. I also participated in this program as well and it helped me to identify the specific niche of my product. So where does your product fit in this vast market of products that offer to do similar things? \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 So I-Corps is really important to help you really fine tune your commercialization plan. And you know, I've also participated in other programs that I think are really, really important. For example, the SBIR-STTR workshops and road shows, man, those are some great programs. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 And I'll say that I've attended these programs over and over again because each time that I go or I participate, I learn something new. And it reminds you of all of the options that are available to really push your product forward. So it's a great idea to really attend these workshops and pick up as much knowledge as you can in order to push, push your technology forward. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 Also, once your grant is funded, I would like to recommend the Women's Innovation Network or WIN. That's a great program. It provides a supportive community of female SBIR-STTR recipients. It provides mentoring. We have speakers who talk about different aspects of commercialization, and it provides an opportunity for female investigators to network with each other, and to be a little vulnerable. And by being vulnerable, we can help each other, and so I recommend that as well. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 I'd also like to recommend, for those who are seeking to develop a business, a biotechnology business for their laboratory discoveries, you may have some local resources that you can tap into. Many states have different biotechnology professional organizations that put on workshops and they -- some provide funding. And they provide different types of education about entrepreneurship. \u00A0 \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 So there may be some local organizations that you can also take part in, in order to learn, to build your business. And I would probably start to find out about if your state has a similar organization. Maybe start in your office of technology transfer, because that's the location where, in academia, that's kind of the line between academia and the commercial environment. So I would start there to find out if there are some local organizations that can also help you to get where you need to go. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 MICHAEL: Yeah. And really thanks so much for bringing some of these programs up. Rukiyah. One of the things that I like to talk about, when I talk about our SBIR program is, I think people understand that SBIR provides funding, which is obviously the most critical element. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 The way I like to think of it is it's necessary, obviously, but it's not sufficient. You know, you\u2019re small business, you need funding obviously, but you need access to a whole range of different resources in addition to funding. So that's one of the things that separates the NCI SBIR program, I think, from others in that we really put a lot of time into thinking about and creating resource programs that our companies need. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 So just as an example, you mentioned I-Corps, that was one program we created here at NCI SBIR for the NIH as a whole. But we also offer our Investor Initiatives Program, too, where we are able to connect companies that we're funding through our SBIR program with private investors. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 So that, you know, as you're developing your drug, you're in the earlier stages now, you're obviously going to need to go out and raise additional capital. Because we're the NCI, we're able to develop relationships with some of the largest investors around the country, whether that's large pharmaceutical companies or some of the large venture capital funds around the country that invest in the cancer space. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 So once a year, we invite all the companies that we are funding in our portfolio to go through our Investor Initiatives Program. And that's an opportunity for you to put together a short application, which will then be reviewed by a panel of investors. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 And then those investors help us identify companies that are ready to go out and present and pitch their technology to, to other investors in order to help raise capital. And then we also do pitch coaching, to help, to help prepare our companies to, to go out and present. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 RUKIYAH: I can say that that's really important because in this current climate, it's very difficult to raise funds. So having that edge, having those connections would be very helpful. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 MICHAEL: I was wondering, maybe you could provide some advice. You mentioned the WIN Program as an example, you know, a program that we offer to women entrepreneurs in our program, and give them the opportunity to come together and really kind of share lessons learned. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 In addition to that, do you have any other advice for women in academia who want to transfer their technology and really kind of start that journey towards a start up? \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 RUKIYAH: Sure. You know, the first thing that I would say is that this is very doable. It's doable because women have some ingrained properties that are really conducive to making this happen. For example, our ability to multitask is very important and very critical for getting this job done. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 And so the job of transferring the technology into the commercial space takes a lot of multitasking. You can work with different people in order to get things done. Collaboration, that's also another property that we have as academics, and so we can collaborate with people in order to get things done. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 And so for me personally, one of the things that I had to resist was the urge to be Superwoman. And so for me, what I usually try to do is do everything myself and, you know, try to achieve it all by myself, and that's really not the way to go. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 What you - What is successful is to collaborate and delegate in order to achieve your goals. So that's one of the things that I would say that we really have to do as women, collaborate, don't try to do it all, find the experts and let the experts do what they know how to do. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 And then finally, I would say in terms of advice for women, I would say ask for what you want. Sometimes we don't like to ask and -- ask people for help or ask for resources, but you have to ask, all, all that can be said is either yes or no. So just ask and if the answer is no, try another route and keep moving forward. Don't take it personally, just keep moving forward. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 MICHAEL: I really think that's -- I think -- I really think that's excellent advice. There's, there's another program really focusing on academics doing the research, developing a technology who are interested in making that transition. There's another program that we offer called the Small Business Transition Grant. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 It's a fairly new program, not a lot of folks are, are aware of it, but we're really trying to, to increase the awareness of that program and that, that program, we actually developed in response to conversations we were having with our cancer centers from across the country, where we were trying to figure out what can the NCI do to facilitate the translation of academic technologies and to get more technologies out of the lab and into small companies. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 And one of the key funding gaps that they told us was existing, was that it was really hard for early career academics, like post-docs, to raise funds. You know, there was kind of a dearth of funding when, when you're really at the early stages in your career trying to raise funding. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 So the Small Business Transition Grant actually is focused on, on post-docs and other early career academics, and it will provide funding to them while they're still at the university, both for their research as well as funding for both a technical mentor and a business mentor. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 And the whole goal is to provide kind of the, the support that that early-career academic needs, you know, sounds -- and it sounds like you were kind of in that same situation, but the goal is to provide funding as well as mentorship support to that early-career academic to help them as they're looking to move their technology out of a university to a small business. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 You can apply for either just a Phase 1 application or you can go for a combined Phase 1/Phase 2 application. And the funding will support the academic, first at the university, and then as they move their technology to a company, and they move -- and they advance that technology to a Phase 2, it'll continue that same support. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 So, it's another program that we have tried to tailor to the needs of you and other academics that are out there looking to apply. And, again, we have information about the Small Business Transition Grant up on our website at sbir.cancer.gov. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 We're actually going to be launching that program for the coming year sometime in, in March. So if you're interested in that, and I encourage everyone to, again, go up on our website to get more information and talk to a program director, reach out to us, send us an e-mail, and we're happy to give you more information about that program. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 RUKIYAH: Sounds like a really interesting project. I think it's a great idea because young -- Generation Z, Young investigators, they want to own businesses, a very different mentality from previous generations. So this type of program sounds like it would be really great to help to launch their ideas and their businesses in the biotech space. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 MICHAEL: Absolutely. And that's what we're trying to do with that, that program right now. It's, again, it's still a fairly young program, so we're, we're trying to, we're trying to talk about it a little bit more with folks like yourself to just kind of raise visibility that that's, that's a funding opportunity that an academic who's interested in moving to a small business, maybe creating their own small business, it's a funding opportunity that's, that's available to help to, to help support them on that. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 Well, this has been great. I've really enjoyed our conversation. I wanted to ask you just one last question, and that's, is there one piece of advice that you'd like to leave folks with before we leave today regarding, you know, your journey or their journey as they're looking to start it? \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 RUKIYAH: Sure. I would say the best piece of advice that I can give is to use your skills that you have acquired as an academic researcher to start and grow your company. The skills that are necessary to make this work include: collaboration, persistence. You have to be persistent, networking. And so you can also use your passion, what is it that you really feel passionate about in order to keep the process moving forward? \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 And then I would also advise you to take advantage of the resources that are available to help you with commercialization of biotechnology products. I would also say, as you mentioned, this is a very long drawn out process. So I would advise you to know what the process is, but don't focus on the big picture, focus on your milestones, because if you get focused on how big this whole process is, it's discouraging, right, and it may prevent you from moving forward. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 So just break your process up into milestones, achieve your next milestone, and, and view it from that perspective, rather than being focused on all that needs to be done. And I think that that has been really helpful to me to just kind of take this at small pieces. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 MICHAEL: Excellent advice, break it down step-by-step and if you can work on it step-by-step, then it's not such an overwhelming kind of thing, you know, set your goals, achieve that one goal, and move to the next one. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 Well, this has been wonderful. I've really enjoyed our conversation today. Thank you for taking the time. And I know it's going to be really valuable to a lot of the folks out in the community who are interested in coming back and applying for NCI SBIR. We look forward to working together with you in the future. And again, thank you. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 RUKIYAH: Thank you so much for inviting me to talk. I hope that some of the information that I've shared will be helpful to someone. And it is great to be part of a community of people who are really devoted to developing cancer chemotherapeutics. And again, I just thank you for the invitation. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 MICHAEL: Thank you. Thanks so much Rukiyah for speaking with us today. We really look forward to seeing Claradele\u2019s continued growth and making positive patient impact. As always, don't forget to check out our website, sbir.cancer.gov, for the latest funding opportunities and commercialization resources to support your journey from lab to market. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 This was Michael Weingarten from NCI SBIR. Please join us again for the next installment of NCI SBIR Innovation Lab and subscribe today wherever you listen. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 If you have questions about cancer or comments about this podcast, e-mail us at nciinfo@nih.gov or call us at 1-800-422-6237 and please be sure to mention Innovation Lab in your query. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 We are a production of the US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Thanks so much for listening. \u00A0 \u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0\u00A0 [music] \u00A0 END OF FILE \u00A0 \u00A0","datePublished":"2024-03-20","potentialAction":{"@type":"ListenAction","target":[{"@type":"EntryPoint","urlTemplate":"https://open.spotify.com/episode/0BUwq1DLQg9KAFG1jaV4mC?autoplay=true","actionPlatform":["http://schema.org/DesktopWebPlatform","http://schema.org/IOSPlatform","http://schema.googleapis.com/GoogleAudioCast","http://schema.googleapis.com/GoogleVideoCast"]},"android-app://com.spotify.music/spotify/episode/0BUwq1DLQg9KAFG1jaV4mC/play"],"expectsAcceptanceOf":{"@type":"Offer","category":"free","eligibleRegion":[{"@type":"Country","name":"AD"},{"@type":"Country","name":"AE"},{"@type":"Country","name":"AG"},{"@type":"Country","name":"AL"},{"@type":"Country","name":"AM"},{"@type":"Country","name":"AO"},{"@type":"Country","name":"AR"},{"@type":"Country","name":"AT"},{"@type":"Country","name":"AU"},{"@type":"Country","name":"AZ"},{"@type":"Country","name":"BA"},{"@type":"Country","name":"BB"},{"@type":"Country","name":"BE"},{"@type":"Country","name":"BF"},{"@type":"Country","name":"BG"},{"@type":"Country","name":"BH"},{"@type":"Country","name":"BI"},{"@type":"Country","name":"BJ"},{"@type":"Country","name":"BN"},{"@type":"Country","name":"BO"},{"@type":"Country","name":"BR"},{"@type":"Country","name":"BS"},{"@type":"Country","name":"BT"},{"@type":"Country","name":"BW"},{"@type":"Country","name":"BZ"},{"@type":"Country","name":"CA"},{"@type":"Country","name":"CH"},{"@type":"Country","name":"CI"},{"@type":"Country","name":"CL"},{"@type":"Country","name":"CM"},{"@type":"Country","name":"CO"},{"@type":"Country","name":"CR"},{"@type":"Country","name":"CV"},{"@type":"Country","name":"CW"},{"@type":"Country","name":"CY"},{"@type":"Country","name":"CZ"},{"@type":"Country","name":"DE"},{"@type":"Country","name":"DJ"},{"@type":"Country","name":"DK"},{"@type":"Country","name":"DM"},{"@type":"Country","name":"DO"},{"@type":"Country","name":"DZ"},{"@type":"Country","name":"EC"},{"@type":"Country","name":"EE"},{"@type":"Country","name":"EG"},{"@type":"Country","name":"ES"},{"@type":"Country","name":"FI"},{"@type":"Country","name":"FJ"},{"@type":"Country","name":"FM"},{"@type":"Country","name":"FR"},{"@type":"Country","name":"GA"},{"@type":"Country","name":"GB"},{"@type":"Country","name":"GD"},{"@type":"Country","name":"GE"},{"@type":"Country","name":"GH"},{"@type":"Country","name":"GM"},{"@type":"Country","name":"GN"},{"@type":"Country","name":"GQ"},{"@type":"Country","name":"GR"},{"@type":"Country","name":"GT"},{"@type":"Country","name":"GW"},{"@type":"Country","name":"GY"},{"@type":"Country","name":"HK"},{"@type":"Country","name":"HN"},{"@type":"Country","name":"HR"},{"@type":"Country","name":"HT"},{"@type":"Country","name":"HU"},{"@type":"Country","name":"ID"},{"@type":"Country","name":"IE"},{"@type":"Country","name":"IL"},{"@type":"Country","name":"IN"},{"@type":"Country","name":"IS"},{"@type":"Country","name":"IT"},{"@type":"Country","name":"JM"},{"@type":"Country","name":"JO"},{"@type":"Country","name":"JP"},{"@type":"Country","name":"KE"},{"@type":"Country","name":"KH"},{"@type":"Country","name":"KI"},{"@type":"Country","name":"KM"},{"@type":"Country","name":"KN"},{"@type":"Country","name":"KR"},{"@type":"Country","name":"KW"},{"@type":"Country","name":"LA"},{"@type":"Country","name":"LB"},{"@type":"Country","name":"LC"},{"@type":"Country","name":"LI"},{"@type":"Country","name":"LR"},{"@type":"Country","name":"LS"},{"@type":"Country","name":"LT"},{"@type":"Country","name":"LU"},{"@type":"Country","name":"LV"},{"@type":"Country","name":"MA"},{"@type":"Country","name":"MC"},{"@type":"Country","name":"ME"},{"@type":"Country","name":"MG"},{"@type":"Country","name":"MH"},{"@type":"Country","name":"MK"},{"@type":"Country","name":"ML"},{"@type":"Country","name":"MN"},{"@type":"Country","name":"MO"},{"@type":"Country","name":"MR"},{"@type":"Country","name":"MT"},{"@type":"Country","name":"MU"},{"@type":"Country","name":"MV"},{"@type":"Country","name":"MW"},{"@type":"Country","name":"MX"},{"@type":"Country","name":"MY"},{"@type":"Country","name":"MZ"},{"@type":"Country","name":"NA"},{"@type":"Country","name":"NE"},{"@type":"Country","name":"NG"},{"@type":"Country","name":"NI"},{"@type":"Country","name":"NL"},{"@type":"Country","name":"NO"},{"@type":"Country","name":"NP"},{"@type":"Country","name":"NR"},{"@type":"Country","name":"NZ"},{"@type":"Country","name":"OM"},{"@type":"Country","name":"PA"},{"@type":"Country","name":"PE"},{"@type":"Country","name":"PG"},{"@type":"Country","name":"PH"},{"@type":"Country","name":"PL"},{"@type":"Country","name":"PR"},{"@type":"Country","name":"PS"},{"@type":"Country","name":"PT"},{"@type":"Country","name":"PW"},{"@type":"Country","name":"PY"},{"@type":"Country","name":"QA"},{"@type":"Country","name":"RO"},{"@type":"Country","name":"RS"},{"@type":"Country","name":"RW"},{"@type":"Country","name":"SA"},{"@type":"Country","name":"SB"},{"@type":"Country","name":"SC"},{"@type":"Country","name":"SE"},{"@type":"Country","name":"SG"},{"@type":"Country","name":"SI"},{"@type":"Country","name":"SK"},{"@type":"Country","name":"SL"},{"@type":"Country","name":"SM"},{"@type":"Country","name":"SN"},{"@type":"Country","name":"SR"},{"@type":"Country","name":"ST"},{"@type":"Country","name":"SV"},{"@type":"Country","name":"SZ"},{"@type":"Country","name":"TD"},{"@type":"Country","name":"TG"},{"@type":"Country","name":"TH"},{"@type":"Country","name":"TL"},{"@type":"Country","name":"TN"},{"@type":"Country","name":"TO"},{"@type":"Country","name":"TR"},{"@type":"Country","name":"TT"},{"@type":"Country","name":"TV"},{"@type":"Country","name":"TW"},{"@type":"Country","name":"TZ"},{"@type":"Country","name":"UA"},{"@type":"Country","name":"US"},{"@type":"Country","name":"UY"},{"@type":"Country","name":"UZ"},{"@type":"Country","name":"VC"},{"@type":"Country","name":"VN"},{"@type":"Country","name":"VU"},{"@type":"Country","name":"WS"},{"@type":"Country","name":"XK"},{"@type":"Country","name":"ZA"},{"@type":"Country","name":"ZM"},{"@type":"Country","name":"ZW"}]}}}</script><link rel="manifest" href="https://open.spotifycdn.com/cdn/generated/manifest-mobile-web-player.a1ddf51c.json"/><style data-styled="active"></style><style data-styled="" data-styled-version="5.3.11">.bksmLQ{box-sizing:border-box;-webkit-tap-highlight-color:transparent;background-color:transparent;border:0;border-radius:var(--encore-button-corner-radius,9999px);cursor:pointer;display:inline-block;position:relative;text-align:center;-webkit-text-decoration:none;text-decoration:none;text-transform:none;touch-action:manipulation;-webkit-transition-duration:33ms;transition-duration:33ms;-webkit-transition-property:background-color,border-color,color,box-shadow,filter,-webkit-transform;-webkit-transition-property:background-color,border-color,color,box-shadow,filter,transform;transition-property:background-color,border-color,color,box-shadow,filter,transform;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;vertical-align:middle;-webkit-transform:translate3d(0,0,0);-ms-transform:translate3d(0,0,0);transform:translate3d(0,0,0);color:var(--text-subdued,#656565);min-inline-size:0;min-block-size:var(--encore-control-size-base,48px);padding-block:var(--encore-spacing-tighter,12px);padding-inline:var(--encore-spacing-tighter,12px);display:-webkit-inline-box;display:-webkit-inline-flex;display:-ms-inline-flexbox;display:inline-flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-box-pack:center;-webkit-justify-content:center;-ms-flex-pack:center;justify-content:center;}/*!sc*/ @supports (overflow-wrap:anywhere){.bksmLQ{overflow-wrap:anywhere;}}/*!sc*/ @supports not (overflow-wrap:anywhere){.bksmLQ{word-break:break-word;}}/*!sc*/ .bksmLQ:hover{-webkit-transform:scale(1.04);-ms-transform:scale(1.04);transform:scale(1.04);color:var(--text-base,#000000);}/*!sc*/ .bksmLQ:active{opacity:0.7;outline:none;-webkit-transform:scale(1);-ms-transform:scale(1);transform:scale(1);color:var(--text-subdued,#656565);}/*!sc*/ .bksmLQ::after{inline-size:24px;}/*!sc*/ .bksmLQ[disabled],.bksmLQ[aria-disabled='true'],fieldset[disabled] .bksmLQ{cursor:not-allowed;opacity:0.3;-webkit-transform:scale(1);-ms-transform:scale(1);transform:scale(1);color:var(--text-subdued,#656565);}/*!sc*/ .bksmLQ[disabled]::before,.bksmLQ[aria-disabled='true']::before,fieldset[disabled] .bksmLQ::before{background-color:transparent;}/*!sc*/ .bksmLQ[disabled]::after,.bksmLQ[aria-disabled='true']::after,fieldset[disabled] .bksmLQ::after{border-color:transparent;}/*!sc*/ .kTFJuL{box-sizing:border-box;-webkit-tap-highlight-color:transparent;background-color:transparent;border:0;border-radius:var(--encore-button-corner-radius,9999px);cursor:pointer;display:inline-block;position:relative;text-align:center;-webkit-text-decoration:none;text-decoration:none;text-transform:none;touch-action:manipulation;-webkit-transition-duration:33ms;transition-duration:33ms;-webkit-transition-property:background-color,border-color,color,box-shadow,filter,-webkit-transform;-webkit-transition-property:background-color,border-color,color,box-shadow,filter,transform;transition-property:background-color,border-color,color,box-shadow,filter,transform;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;vertical-align:middle;-webkit-transform:translate3d(0,0,0);-ms-transform:translate3d(0,0,0);transform:translate3d(0,0,0);color:var(--text-base,#000000);min-inline-size:0;padding:0;display:-webkit-inline-box;display:-webkit-inline-flex;display:-ms-inline-flexbox;display:inline-flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-box-pack:center;-webkit-justify-content:center;-ms-flex-pack:center;justify-content:center;}/*!sc*/ @supports (overflow-wrap:anywhere){.kTFJuL{overflow-wrap:anywhere;}}/*!sc*/ @supports not (overflow-wrap:anywhere){.kTFJuL{word-break:break-word;}}/*!sc*/ .kTFJuL:hover{-webkit-transform:scale(1.04);-ms-transform:scale(1.04);transform:scale(1.04);}/*!sc*/ .kTFJuL:active{opacity:0.7;outline:none;-webkit-transform:scale(1);-ms-transform:scale(1);transform:scale(1);color:var(--text-base,#000000);}/*!sc*/ .kTFJuL::after{inline-size:100%;}/*!sc*/ .kTFJuL[disabled],.kTFJuL[aria-disabled='true'],fieldset[disabled] .kTFJuL{cursor:not-allowed;opacity:0.3;-webkit-transform:scale(1);-ms-transform:scale(1);transform:scale(1);color:var(--text-base,#000000);}/*!sc*/ .kTFJuL[disabled]::before,.kTFJuL[aria-disabled='true']::before,fieldset[disabled] .kTFJuL::before{background-color:transparent;}/*!sc*/ .kTFJuL[disabled]::after,.kTFJuL[aria-disabled='true']::after,fieldset[disabled] .kTFJuL::after{border-color:transparent;}/*!sc*/ .hRqQQR{box-sizing:border-box;-webkit-tap-highlight-color:transparent;background-color:transparent;border:0;border-radius:var(--encore-button-corner-radius,9999px);cursor:pointer;display:inline-block;position:relative;text-align:center;-webkit-text-decoration:none;text-decoration:none;text-transform:none;touch-action:manipulation;-webkit-transition-duration:33ms;transition-duration:33ms;-webkit-transition-property:background-color,border-color,color,box-shadow,filter,-webkit-transform;-webkit-transition-property:background-color,border-color,color,box-shadow,filter,transform;transition-property:background-color,border-color,color,box-shadow,filter,transform;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;vertical-align:middle;-webkit-transform:translate3d(0,0,0);-ms-transform:translate3d(0,0,0);transform:translate3d(0,0,0);color:var(--text-base,#000000);min-inline-size:0;min-block-size:var(--encore-control-size-base,48px);padding-block:calc(var(--encore-spacing-tighter-2,8px) - 2px);padding-inline:0;display:-webkit-inline-box;display:-webkit-inline-flex;display:-ms-inline-flexbox;display:inline-flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-box-pack:center;-webkit-justify-content:center;-ms-flex-pack:center;justify-content:center;}/*!sc*/ @supports (overflow-wrap:anywhere){.hRqQQR{overflow-wrap:anywhere;}}/*!sc*/ @supports not (overflow-wrap:anywhere){.hRqQQR{word-break:break-word;}}/*!sc*/ .hRqQQR:hover{-webkit-transform:scale(1.04);-ms-transform:scale(1.04);transform:scale(1.04);}/*!sc*/ .hRqQQR:active{opacity:0.7;outline:none;-webkit-transform:scale(1);-ms-transform:scale(1);transform:scale(1);color:var(--text-base,#000000);}/*!sc*/ .hRqQQR::after{inline-size:100%;}/*!sc*/ .hRqQQR[disabled],.hRqQQR[aria-disabled='true'],fieldset[disabled] .hRqQQR{cursor:not-allowed;opacity:0.3;-webkit-transform:scale(1);-ms-transform:scale(1);transform:scale(1);color:var(--text-base,#000000);}/*!sc*/ .hRqQQR[disabled]::before,.hRqQQR[aria-disabled='true']::before,fieldset[disabled] .hRqQQR::before{background-color:transparent;}/*!sc*/ .hRqQQR[disabled]::after,.hRqQQR[aria-disabled='true']::after,fieldset[disabled] .hRqQQR::after{border-color:transparent;}/*!sc*/ data-styled.g2[id="Button-sc-1dqy6lx-0"]{content:"bksmLQ,kTFJuL,hRqQQR,"}/*!sc*/ .hYdsxw{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;}/*!sc*/ .kUVYXR{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;margin-inline-start:12px;}/*!sc*/ data-styled.g3[id="IconWrapper__Wrapper-sc-16usrgb-0"]{content:"hYdsxw,kUVYXR,"}/*!sc*/ .bneLcE{fill:currentcolor;width:var(--encore-graphic-size-decorative-base,24px);height:var(--encore-graphic-size-decorative-base,24px);}/*!sc*/ .bneLcE *{vector-effect:non-scaling-stroke;}/*!sc*/ .zsGU{fill:currentcolor;width:var(--encore-graphic-size-decorative-base,24px);height:var(--encore-graphic-size-decorative-base,24px);}/*!sc*/ .zsGU *{vector-effect:non-scaling-stroke;}/*!sc*/ [dir='rtl'] .zsGU.zsGU{-webkit-transform:scaleX(-1);-ms-transform:scaleX(-1);transform:scaleX(-1);}/*!sc*/ data-styled.g4[id="Svg-sc-ytk21e-0"]{content:"bneLcE,zsGU,"}/*!sc*/ .hKFGwn{box-sizing:border-box;-webkit-tap-highlight-color:transparent;position:relative;background-color:var(--background-base,#1ed760);color:var(--text-base,#000000);display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;border-radius:var(--encore-button-corner-radius,9999px);font-size:inherit;min-block-size:var(--encore-control-size-larger,56px);-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-box-pack:center;-webkit-justify-content:center;-ms-flex-pack:center;justify-content:center;inline-size:var(--encore-control-size-larger,56px);-webkit-block-size:var(--encore-control-size-larger,56px);-ms-flex-block-size:var(--encore-control-size-larger,56px);block-size:var(--encore-control-size-larger,56px);-webkit-transition-property:background-color,-webkit-transform;-webkit-transition-property:background-color,transform;transition-property:background-color,transform;-webkit-transition-duration:33ms;transition-duration:33ms;}/*!sc*/ @supports (overflow-wrap:anywhere){.hKFGwn{overflow-wrap:anywhere;}}/*!sc*/ @supports not (overflow-wrap:anywhere){.hKFGwn{word-break:break-word;}}/*!sc*/ data-styled.g6[id="ButtonInner-sc-14ud5tc-0"]{content:"hKFGwn,"}/*!sc*/ .dlTJiR{box-sizing:border-box;-webkit-tap-highlight-color:transparent;background-color:transparent;border:0;border-radius:var(--encore-button-corner-radius,9999px);cursor:pointer;display:inline-block;position:relative;text-align:center;-webkit-text-decoration:none;text-decoration:none;text-transform:none;touch-action:manipulation;-webkit-transition-duration:33ms;transition-duration:33ms;-webkit-transition-property:background-color,border-color,color,box-shadow,filter,-webkit-transform;-webkit-transition-property:background-color,border-color,color,box-shadow,filter,transform;transition-property:background-color,border-color,color,box-shadow,filter,transform;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;vertical-align:middle;-webkit-transform:translate3d(0,0,0);-ms-transform:translate3d(0,0,0);transform:translate3d(0,0,0);padding:0;min-inline-size:0;-webkit-align-self:center;-ms-flex-item-align:center;align-self:center;}/*!sc*/ .dlTJiR:hover .ButtonInner-sc-14ud5tc-0,.dlTJiR:hover .ButtonFocus-sc-2hq6ey-0{-webkit-transform:scale(1.04);-ms-transform:scale(1.04);transform:scale(1.04);}/*!sc*/ .dlTJiR:hover .ButtonInner-sc-14ud5tc-0{background-color:var(--background-highlight,#3be477);}/*!sc*/ .dlTJiR:active .ButtonInner-sc-14ud5tc-0{background-color:var(--background-press,#1abc54);box-shadow:none;-webkit-transform:scale(1);-ms-transform:scale(1);transform:scale(1);}/*!sc*/ .dlTJiR:active .ButtonFocus-sc-2hq6ey-0{-webkit-transform:scale(1);-ms-transform:scale(1);transform:scale(1);}/*!sc*/ .dlTJiR:focus .ButtonFocus-sc-2hq6ey-0{border-color:var(--parents-essential-base,var(--essential-base,#000000));}/*!sc*/ .dlTJiR[disabled] .ButtonInner-sc-14ud5tc-0,.dlTJiR[aria-disabled='true'] .ButtonInner-sc-14ud5tc-0,fieldset[disabled] .dlTJiR .ButtonInner-sc-14ud5tc-0{cursor:not-allowed;opacity:0.3;-webkit-transform:scale(1);-ms-transform:scale(1);transform:scale(1);background-color:var(--background-base,#1ed760);color:var(--text-base,#000000);}/*!sc*/ .dlTJiR[disabled] .ButtonFocus-sc-2hq6ey-0,.dlTJiR[aria-disabled='true'] .ButtonFocus-sc-2hq6ey-0,fieldset[disabled] .dlTJiR .ButtonFocus-sc-2hq6ey-0{border-color:transparent;}/*!sc*/ data-styled.g7[id="Button-sc-qlcn5g-0"]{content:"dlTJiR,"}/*!sc*/ .ivomLs{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;position:absolute;inset-block-start:calc((var(--encore-control-size-larger,56px) - var(--encore-graphic-size-decorative-base,24px)) / 2);inset-inline-start:calc((var(--encore-control-size-larger,56px) - var(--encore-graphic-size-decorative-base,24px)) / 2);}/*!sc*/ data-styled.g8[id="IconWrapper__Wrapper-sc-1hf1hjl-0"]{content:"ivomLs,"}/*!sc*/ .kOChlU{inline-size:100%;border-radius:var(--encore-corner-radius-base,4px);}/*!sc*/ data-styled.g15[id="Image-sc-1u215sg-3"]{content:"kOChlU,"}/*!sc*/ .lmgIvZ{display:-webkit-box;-webkit-line-clamp:2;-webkit-box-orient:vertical;overflow:hidden;}/*!sc*/ data-styled.g19[id="ListRowTitle__LineClamp-sc-1xe2if1-0"]{content:"lmgIvZ,"}/*!sc*/ .eFGzcP{outline:none;-webkit-text-decoration:none;text-decoration:none;}/*!sc*/ @supports (overflow-wrap:anywhere){.eFGzcP{overflow-wrap:anywhere;}}/*!sc*/ @supports not (overflow-wrap:anywhere){.eFGzcP{word-break:break-word;}}/*!sc*/ data-styled.g20[id="ListRowTitle__ListRowText-sc-1xe2if1-1"]{content:"eFGzcP,"}/*!sc*/ .wLcyr{box-sizing:border-box;-webkit-tap-highlight-color:transparent;position:relative;border-radius:var(--encore-corner-radius-larger,6px);min-block-size:48px;z-index:0;color:var(--text-base,#000000);padding-block-start:8px;padding-block-end:8px;padding-inline-start:8px;padding-inline-end:8px;--animation-speed:300ms;--animation-ease:ease;--bg-inset-change-press:-4px;cursor:pointer;}/*!sc*/ .wLcyr::after{content:'';position:absolute;border-radius:var(--encore-corner-radius-larger,6px);z-index:-1;-webkit-transition:background-color var(--animation-speed) var(--animation-ease),top var(--animation-speed) var(--animation-ease),left var(--animation-speed) var(--animation-ease),right var(--animation-speed) var(--animation-ease),bottom var(--animation-speed) var(--animation-ease);transition:background-color var(--animation-speed) var(--animation-ease),top var(--animation-speed) var(--animation-ease),left var(--animation-speed) var(--animation-ease),right var(--animation-speed) var(--animation-ease),bottom var(--animation-speed) var(--animation-ease);inset:0;inset:8px 8px 8px 8px;}/*!sc*/ .wLcyr[disabled],.wLcyr[aria-disabled='true'],fieldset[disabled] .wLcyr{cursor:not-allowed;opacity:0.3;-webkit-transform:scale(1);-ms-transform:scale(1);transform:scale(1);}/*!sc*/ .wLcyr:hover::after{background-color:var(--background-highlight,#f5f5f5);inset:0;}/*!sc*/ .wLcyr[disabled]:hover::after,.wLcyr[aria-disabled='true']:hover::after{background-color:unset;}/*!sc*/ .wLcyr[disabled]:active::after,.wLcyr[aria-disabled='true']:active::after{background-color:unset;inset:unset;}/*!sc*/ data-styled.g29[id="Box__BoxComponent-sc-y4nds-0"]{content:"wLcyr,"}/*!sc*/ .MWEhk button,.MWEhk a,.MWEhk [role='button'],.MWEhk [role='link']{position:relative;z-index:1;}/*!sc*/ data-styled.g37[id="Areas__InteractiveArea-sc-1tea2mc-0"]{content:"MWEhk,"}/*!sc*/ .kLALqL{-webkit-column-gap:var(--encore-spacing-tighter,12px);column-gap:var(--encore-spacing-tighter,12px);-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;}/*!sc*/ data-styled.g38[id="Areas__MainArea-sc-1tea2mc-1"]{content:"kLALqL,"}/*!sc*/ .cuoMqc{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;gap:2px;-webkit-flex-basis:100%;-ms-flex-preferred-size:100%;flex-basis:100%;-webkit-align-items:flex-start;-webkit-box-align:flex-start;-ms-flex-align:flex-start;align-items:flex-start;}/*!sc*/ data-styled.g39[id="Areas__Column-sc-1tea2mc-2"]{content:"cuoMqc,"}/*!sc*/ .hscyXl{display:-webkit-inline-box;display:-webkit-inline-flex;display:-ms-inline-flexbox;display:inline-flex;-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;row-gap:var(--encore-spacing-tighter-2,8px);}/*!sc*/ .hscyXl[disabled]{opacity:0.7;}/*!sc*/ data-styled.g41[id="Box-sc-1njtxi4-0"]{content:"hscyXl,"}/*!sc*/ .DjiIj{position:absolute;z-index:0;inset:0;cursor:pointer;}/*!sc*/ data-styled.g43[id="CardLink-sc-1ut6cns-0"]{content:"DjiIj,"}/*!sc*/ .gPhSUm{box-sizing:border-box;-webkit-tap-highlight-color:transparent;border:0;border-block-start:1px solid var(--decorative-subdued,#dedede);margin-block:var(--encore-spacing-looser,24px);}/*!sc*/ data-styled.g48[id="HorizontalRule__HorizontalRuleElement-sc-198gjx4-0"]{content:"gPhSUm,"}/*!sc*/ </style><link rel="stylesheet" href="https://open.spotifycdn.com/cdn/build/mobile-web-player/mwp-dialog-container.8aa726db.css"/><link rel="stylesheet" href="https://open.spotifycdn.com/cdn/build/mobile-web-player/mwp-context-menu-container.951dcef4.css"/><link rel="stylesheet" href="https://open.spotifycdn.com/cdn/build/mobile-web-player/mwp-connect-view-container.f30325e3.css"/><link rel="stylesheet" href="https://open.spotifycdn.com/cdn/build/mobile-web-player/mwp-now-playing-view.57ed20f7.css"/><link rel="stylesheet" href="https://open.spotifycdn.com/cdn/build/mobile-web-player/mwp-artist-page.7f81179e.css"/><link rel="stylesheet" href="https://open.spotifycdn.com/cdn/build/mobile-web-player/mwp-home-page.0e16afa2.css"/><link rel="stylesheet" href="https://open.spotifycdn.com/cdn/build/mobile-web-player/mobile-web-player.96045797.css"/><link rel="preconnect" href="https://apresolve.spotify.com" crossorigin="anonymous"/><link rel="preconnect" href="https://clienttoken.spotify.com" crossorigin="anonymous"/><link rel="preconnect" href="https://api-partner.spotify.com" crossorigin="anonymous"/><link rel="preconnect" href="https://spclient.wg.spotify.com" crossorigin="anonymous"/><link rel="preconnect" href="https://api.spotify.com" crossorigin="anonymous"/><link rel="preconnect" href="https://daily-mix.scdn.co" crossorigin="anonymous"/><link rel="preconnect" href="https://exp.wg.spotify.com" crossorigin="anonymous"/><link rel="preconnect" href="https://i.scdn.co" crossorigin="anonymous"/><link rel="preconnect" href="https://lineup-images.scdn.co" crossorigin="anonymous"/><link rel="preconnect" href="https://mosaic.scdn.co" crossorigin="anonymous"/><link rel="preconnect" href="https://open.spotifycdn.com" crossorigin="anonymous"/><link rel="preconnect" href="https://pixel-static.spotify.com" crossorigin="anonymous"/><link rel="preconnect" href="https://pixel.spotify.com" crossorigin="anonymous"/><link rel="preconnect" href="https://pl.scdn.co" crossorigin="anonymous"/><link rel="preconnect" href="https://open.spotifycdn.com" crossorigin="anonymous"/><link rel="preconnect" href="https://gae2-dealer.spotify.com" crossorigin="anonymous"/><link rel="preconnect" href="https://gae2-spclient.spotify.com" crossorigin="anonymous"/><link rel="preload" href="https://open.spotifycdn.com/cdn/generated-locales/mobile-web-player/en.4d4a0934.json" data-translations-url-for-locale="en" as="fetch" crossorigin="anonymous" type="application/json"/><link rel="search" type="application/opensearchdescription+xml" title="Spotify" href="https://open.spotifycdn.com/cdn/generated/opensearch.4cd8879e.xml"/><script defer="" src="https://www.googleoptimize.com/optimize.js?id=GTM-W53X654"></script><script defer="" src="https://open.spotifycdn.com/cdn/js/gtm.ea4c34bc.js"></script><script defer="" src="https://open.spotifycdn.com/cdn/js/retargeting-pixels.5ab9cdc0.js"></script></head><body class="mobile-web-player"><script id="config" data-testid="config" type="application/json">{"appName":"web_player_prototype","market":"SG","locale":{"locale":"en","rtl":false,"textDirection":"ltr"},"isPremium":false,"correlationId":"a3d68913be95d4c74b8eb4c449c831e8","isAnonymous":true,"gtmId":"GTM-PZHN3VD","optimizeId":"GTM-W53X654","pipResources":{"scripts":["https://open.spotifycdn.com/cdn/build/web-player/vendor~web-player.f97f7070.js","https://open.spotifycdn.com/cdn/build/web-player/pip-mini-player.e05b8bdd.js"],"styles":["https://open.spotifycdn.com/cdn/build/web-player/pip-mini-player.1db08a40.css"]},"retargetingPixels":null,"recaptchaWebPlayerFraudSiteKey":"6LfCVLAUAAAAALFwwRnnCJ12DalriUGbj8FW_J39"}</script><script id="session" data-testid="session" type="application/json">{"accessToken":"BQC7HKKDeiNwpxSS3t2erPRnAGHMF8CfxMzZBEhUmu70VF6yAoNRd2L0lNKvvUtWmbnyZZb0095TKfapQ6ijMZfc6Vjo__EJiiUkhe0c8hfb70U2-7c","accessTokenExpirationTimestampMs":1732414067423,"isAnonymous":true,"clientId":"f6a40776580943a7bc5173125a1e8832"}</script><div id="main" data-ssr="1"><div class="encore-layout-themes"><div class="ufy3rNNsNBx6IOixSXEG"><div class="encore-dark-theme xXxkvFpB54Fne7ykRnXa" data-main-scrollable-node="true"><div class="Cv2QMWaKhio30Ly6ooMy"><div class="SAvutxFsWpINsq8pSOqb" style="--bottomMargin:0px"><div data-testid="podcast-entity-view" class="E34FrewmewkuBM1IDQsg"><div class="M2zTPqWSULZAGKARgjXG" style="background:linear-gradient(#6A7988 0%, transparent 100%)"><div class="LTYHCckz80h0rAHEj0aQ OgFUAo4HM9zkORh6yYKs lBPLQvOs6NEAQQaTuYm9" data-testid="entity-header-top-section"><div class="cfggPp9bWTWmJHtaMuwE"><div data-testid="entity-image" style="opacity:1;width:56px;height:56px" class="_9oqBtpu3TVycIiibYRVw"><img aria-hidden="false" draggable="false" loading="eager" src="https://lite-images-i.scdn.co/image/ab67656300005f1f47af993b6b750468dbd95041" data-testid="entity-header-entity-image" alt="" class="mMx2LUixlnN_Fu45JpFB"/></div></div><div class="cfggPp9bWTWmJHtaMuwE"><div class="zJT83mTjBmPlNfEnuNYs" data-testid="entity-header-title-and-subtitle-section"><h1 class="encore-text encore-text-title-medium gj6rSoF7K4FohS2DJDEm" data-encore-id="text" data-testid="showTitle">Episode 6. Entrepreneur Spotlight: Rukiyah Van Dross-Anderson, Claradele Pharmaceuticals</h1><div class="encore-text encore-text-body-small sMT6JaxLhI2QLVSevX_3 fjP8GyQyM5IWQvTxWk6W" data-encore-id="text" data-testid="entity-header-entity-subtitle">SBIR Innovation Lab</div></div></div></div><div class="kVj4O1X1hlTwIyajGjJb" data-testid="entity-bottom-section"><span><div class="qfYkuLpETFW3axnfMntO"><p class="encore-text encore-text-body-small _q93agegdE655O5zPz6l" data-encore-id="text">Mar 20</p><p class="encore-text encore-text-body-small _q93agegdE655O5zPz6l" data-encore-id="text" data-testid="episode-progress-not-played"><span class="UyzJidwrGk3awngSGIwv">39 min 32 sec</span></p></div></span><div class="encore-text encore-text-body-small jXbmfyIkvfBoDgVxAaDD" data-encore-id="text"><button class="Button-sc-1dqy6lx-0 bksmLQ" aria-label="Save to Your Library" data-encore-id="buttonTertiary"><span aria-hidden="true" class="IconWrapper__Wrapper-sc-16usrgb-0 hYdsxw"><svg data-encore-id="icon" role="img" aria-hidden="true" viewBox="0 0 24 24" class="Svg-sc-ytk21e-0 bneLcE"><path d='M11.999 3a9 9 0 1 0 0 18 9 9 0 0 0 0-18zm-11 9c0-6.075 4.925-11 11-11s11 4.925 11 11-4.925 11-11 11-11-4.925-11-11z'/><path d='M17.999 12a1 1 0 0 1-1 1h-4v4a1 1 0 1 1-2 0v-4h-4a1 1 0 1 1 0-2h4V7a1 1 0 1 1 2 0v4h4a1 1 0 0 1 1 1z'/></svg></span></button><button data-testid="entity-share-button" class="Button-sc-1dqy6lx-0 bksmLQ" aria-label="Share" data-encore-id="buttonTertiary"><span aria-hidden="true" class="IconWrapper__Wrapper-sc-16usrgb-0 hYdsxw"><svg data-encore-id="icon" role="img" aria-hidden="true" viewBox="0 0 24 24" class="Svg-sc-ytk21e-0 bneLcE"><path d='M18.5 4a1.5 1.5 0 1 0 0 3 1.5 1.5 0 0 0 0-3zM15 5.5a3.5 3.5 0 1 1 1.006 2.455L9 12l7.006 4.045a3.5 3.5 0 1 1-.938 1.768l-6.67-3.85a3.5 3.5 0 1 1 0-3.924l6.67-3.852A3.513 3.513 0 0 1 15 5.5zm-9.5 5a1.5 1.5 0 1 0 0 3 1.5 1.5 0 0 0 0-3zm13 6.5a1.5 1.5 0 1 0-.001 3 1.5 1.5 0 0 0 .001-3z'/></svg></span></button><button data-testid="context-menu-action" class="Button-sc-1dqy6lx-0 bksmLQ" aria-label="More" data-encore-id="buttonTertiary"><span aria-hidden="true" class="IconWrapper__Wrapper-sc-16usrgb-0 hYdsxw"><svg data-encore-id="icon" role="img" aria-hidden="true" viewBox="0 0 24 24" class="Svg-sc-ytk21e-0 bneLcE"><path d='M10.5 4.5a1.5 1.5 0 1 0 3 0 1.5 1.5 0 0 0-3 0zm0 15a1.5 1.5 0 1 0 3 0 1.5 1.5 0 0 0-3 0zm0-7.5a1.5 1.5 0 1 0 3 0 1.5 1.5 0 0 0-3 0z'/></svg></span></button></div><div class="PbbAKgDSKqb_aeaogoiN"><div class="ilFQxSwAuKW7R9upfQxi"><button data-testid="play-button" aria-label="Play" data-encore-id="buttonPrimary" data-is-icon-only="true" class="Button-sc-qlcn5g-0 dlTJiR"><span class="ButtonInner-sc-14ud5tc-0 hKFGwn encore-bright-accent-set"><span aria-hidden="true" class="IconWrapper__Wrapper-sc-1hf1hjl-0 ivomLs"><svg data-encore-id="icon" role="img" aria-hidden="true" viewBox="0 0 24 24" class="Svg-sc-ytk21e-0 bneLcE"><path d='m7.05 3.606 13.49 7.788a.7.7 0 0 1 0 1.212L7.05 20.394A.7.7 0 0 1 6 19.788V4.212a.7.7 0 0 1 1.05-.606z'/></svg></span></span></button></div></div></div></div><div class="AXLhOsSjT3bowfjf42kK"><div><div data-testid="expandable-description"><div class="buqVKMpwHgGMDJFSl54R"><div class="encore-text encore-text-body-small Zbad_ytC5aqG3ZISd4Gw" data-encore-id="text"><span class="encore-text encore-text-body-small encore-internal-color-text-subdued G_f5DJd2sgHWeto5cwbi" data-encore-id="text">NCI SBIR Director Michael Weingarten and Rukiyah Van Dross-Anderson, Founder and CEO of SBIR-funded Claradele Pharmaceuticals discuss the journey from postdoc to biotech startup and how women and underrepresented entrepreneurs with innovative cancer solutions can also leverage SBIR support to move their ideas forward. Listen to this podcast to hear:</span></div> <div class="encore-text encore-text-body-small Zbad_ytC5aqG3ZISd4Gw" data-encore-id="text"><span class="encore-text encore-text-body-small encore-internal-color-text-subdued G_f5DJd2sgHWeto5cwbi" data-encore-id="text">•</span><button class="Button-sc-1dqy6lx-0 kTFJuL encore-text-body-medium-bold" data-encore-id="buttonTertiary"><span class="encore-text encore-text-body-small-bold" data-encore-id="text">… see more</span></button></div></div></div><img class="kjxUv_MHNgEH5IARHdA0" src="https://lite-images-i.scdn.co/image/ab67656300005f1f47af993b6b750468dbd95041" alt="Podcast Episode" loading="lazy"/><a href="/show/4ZgsJahci1QqCScnHHZjEZ"><button class="Button-sc-1dqy6lx-0 hRqQQR encore-text-body-medium-bold" data-encore-id="buttonTertiary">See all episodes<span aria-hidden="true" class="IconWrapper__Wrapper-sc-16usrgb-0 kUVYXR"><svg data-encore-id="icon" role="img" aria-hidden="true" viewBox="0 0 24 24" class="Svg-sc-ytk21e-0 zsGU"><path d='M8.043 2.793a1 1 0 0 0 0 1.414L15.836 12l-7.793 7.793a1 1 0 1 0 1.414 1.414L18.664 12 9.457 2.793a1 1 0 0 0-1.414 0z'/></svg></span></button></a><div data-testid="internal-link-recommender-shelf"><div class="JMgUTIyId0RuU9k6aQaz"><h2 class="encore-text encore-text-title-small" data-encore-id="text" dir="auto">More episodes like this</h2></div><div class="qirFczpKFgQDsNuuzLHP" data-testid="carousel-mwp"><div class="Box__BoxComponent-sc-y4nds-0 wLcyr Box-sc-1njtxi4-0 hscyXl" data-encore-id="card" role="group" aria-labelledby="card-title-2HhhtyW30bgqD5TO2pLJyS"><div class="CardLink-sc-1ut6cns-0 DjiIj"></div><div style="display:none" id="onClickHint2HhhtyW30bgqD5TO2pLJyS"></div><a draggable="false" href="/episode/2HhhtyW30bgqD5TO2pLJyS"><img alt="" style="min-inline-size:152px" data-encore-id="image" src="https://i.scdn.co/image/ab67656300005f1fc0a9253195bd0eaeaf5c5a17" class="Image-sc-1u215sg-3 kOChlU"/></a><div class="Areas__InteractiveArea-sc-1tea2mc-0 Areas__MainArea-sc-1tea2mc-1 MWEhk kLALqL"><div class="Areas__InteractiveArea-sc-1tea2mc-0 Areas__Column-sc-1tea2mc-2 MWEhk cuoMqc"><a draggable="false" href="/episode/2HhhtyW30bgqD5TO2pLJyS"><p class="encore-text encore-text-body-medium ListRowTitle__ListRowText-sc-1xe2if1-1 eFGzcP" data-encore-id="listRowTitle"><span class="ListRowTitle__LineClamp-sc-1xe2if1-0 lmgIvZ">Transformative Oncology Innovations, Ken Keller, President & CEO, Daiichi Sankyo, Inc.</span></p></a></div></div></div><div class="Box__BoxComponent-sc-y4nds-0 wLcyr Box-sc-1njtxi4-0 hscyXl" data-encore-id="card" role="group" aria-labelledby="card-title-4RNuf1UccxAPr5Z1y5B3UM"><div class="CardLink-sc-1ut6cns-0 DjiIj"></div><div style="display:none" id="onClickHint4RNuf1UccxAPr5Z1y5B3UM"></div><a draggable="false" href="/episode/4RNuf1UccxAPr5Z1y5B3UM"><img alt="" style="min-inline-size:152px" data-encore-id="image" src="https://i.scdn.co/image/ab67656300005f1f3775f82afc0f0aa51bd7b50b" class="Image-sc-1u215sg-3 kOChlU"/></a><div class="Areas__InteractiveArea-sc-1tea2mc-0 Areas__MainArea-sc-1tea2mc-1 MWEhk kLALqL"><div class="Areas__InteractiveArea-sc-1tea2mc-0 Areas__Column-sc-1tea2mc-2 MWEhk cuoMqc"><a draggable="false" href="/episode/4RNuf1UccxAPr5Z1y5B3UM"><p class="encore-text encore-text-body-medium ListRowTitle__ListRowText-sc-1xe2if1-1 eFGzcP" data-encore-id="listRowTitle"><span class="ListRowTitle__LineClamp-sc-1xe2if1-0 lmgIvZ">Argenx: Changing Lives with Llamas - [Business Breakdowns, EP.122]</span></p></a></div></div></div><div class="Box__BoxComponent-sc-y4nds-0 wLcyr Box-sc-1njtxi4-0 hscyXl" data-encore-id="card" role="group" aria-labelledby="card-title-0UJJHU66Kz4yokF1I1jGly"><div class="CardLink-sc-1ut6cns-0 DjiIj"></div><div style="display:none" id="onClickHint0UJJHU66Kz4yokF1I1jGly"></div><a draggable="false" href="/episode/0UJJHU66Kz4yokF1I1jGly"><img alt="" style="min-inline-size:152px" data-encore-id="image" src="https://i.scdn.co/image/ab67656300005f1f1d03799a5d846fdb2bb221f7" class="Image-sc-1u215sg-3 kOChlU"/></a><div class="Areas__InteractiveArea-sc-1tea2mc-0 Areas__MainArea-sc-1tea2mc-1 MWEhk kLALqL"><div class="Areas__InteractiveArea-sc-1tea2mc-0 Areas__Column-sc-1tea2mc-2 MWEhk cuoMqc"><a draggable="false" href="/episode/0UJJHU66Kz4yokF1I1jGly"><p class="encore-text encore-text-body-medium ListRowTitle__ListRowText-sc-1xe2if1-1 eFGzcP" data-encore-id="listRowTitle"><span class="ListRowTitle__LineClamp-sc-1xe2if1-0 lmgIvZ">Innovating new cancer-selective biologics with PairX Bio’s Dr. David M. Epstein</span></p></a></div></div></div><div class="Box__BoxComponent-sc-y4nds-0 wLcyr Box-sc-1njtxi4-0 hscyXl" data-encore-id="card" role="group" aria-labelledby="card-title-1rcGWndlmKW8omXaixbaz9"><div class="CardLink-sc-1ut6cns-0 DjiIj"></div><div style="display:none" id="onClickHint1rcGWndlmKW8omXaixbaz9"></div><a draggable="false" href="/episode/1rcGWndlmKW8omXaixbaz9"><img alt="" style="min-inline-size:152px" data-encore-id="image" src="https://i.scdn.co/image/ab67656300005f1fba7f3c37ce5e9a60189bbd6a" class="Image-sc-1u215sg-3 kOChlU"/></a><div class="Areas__InteractiveArea-sc-1tea2mc-0 Areas__MainArea-sc-1tea2mc-1 MWEhk kLALqL"><div class="Areas__InteractiveArea-sc-1tea2mc-0 Areas__Column-sc-1tea2mc-2 MWEhk cuoMqc"><a draggable="false" href="/episode/1rcGWndlmKW8omXaixbaz9"><p class="encore-text encore-text-body-medium ListRowTitle__ListRowText-sc-1xe2if1-1 eFGzcP" data-encore-id="listRowTitle"><span class="ListRowTitle__LineClamp-sc-1xe2if1-0 lmgIvZ">Lovisa Afzelius, Flagship Pioneering 🇸🇪 | Company building, AI | E25</span></p></a></div></div></div><div class="Box__BoxComponent-sc-y4nds-0 wLcyr Box-sc-1njtxi4-0 hscyXl" data-encore-id="card" role="group" aria-labelledby="card-title-5zzeqGhr6lYBByXrJMjzw7"><div class="CardLink-sc-1ut6cns-0 DjiIj"></div><div style="display:none" id="onClickHint5zzeqGhr6lYBByXrJMjzw7"></div><a draggable="false" href="/episode/5zzeqGhr6lYBByXrJMjzw7"><img alt="" style="min-inline-size:152px" data-encore-id="image" src="https://i.scdn.co/image/ab67656300005f1f8ab88a3bae40130baaf47c2f" class="Image-sc-1u215sg-3 kOChlU"/></a><div class="Areas__InteractiveArea-sc-1tea2mc-0 Areas__MainArea-sc-1tea2mc-1 MWEhk kLALqL"><div class="Areas__InteractiveArea-sc-1tea2mc-0 Areas__Column-sc-1tea2mc-2 MWEhk cuoMqc"><a draggable="false" href="/episode/5zzeqGhr6lYBByXrJMjzw7"><p class="encore-text encore-text-body-medium ListRowTitle__ListRowText-sc-1xe2if1-1 eFGzcP" data-encore-id="listRowTitle"><span class="ListRowTitle__LineClamp-sc-1xe2if1-0 lmgIvZ">Innovations in Bioengineering and Education feat. Dr. Sabia Zehra Abidi</span></p></a></div></div></div><div class="Box__BoxComponent-sc-y4nds-0 wLcyr Box-sc-1njtxi4-0 hscyXl" data-encore-id="card" role="group" aria-labelledby="card-title-6j6lfVLJmg7tuSaHZnXJsR"><div class="CardLink-sc-1ut6cns-0 DjiIj"></div><div style="display:none" id="onClickHint6j6lfVLJmg7tuSaHZnXJsR"></div><a draggable="false" href="/episode/6j6lfVLJmg7tuSaHZnXJsR"><img alt="" style="min-inline-size:152px" data-encore-id="image" src="https://i.scdn.co/image/ab67656300005f1fda59417ed749665be5e8620b" class="Image-sc-1u215sg-3 kOChlU"/></a><div class="Areas__InteractiveArea-sc-1tea2mc-0 Areas__MainArea-sc-1tea2mc-1 MWEhk kLALqL"><div class="Areas__InteractiveArea-sc-1tea2mc-0 Areas__Column-sc-1tea2mc-2 MWEhk cuoMqc"><a draggable="false" href="/episode/6j6lfVLJmg7tuSaHZnXJsR"><p class="encore-text encore-text-body-medium ListRowTitle__ListRowText-sc-1xe2if1-1 eFGzcP" data-encore-id="listRowTitle"><span class="ListRowTitle__LineClamp-sc-1xe2if1-0 lmgIvZ">Archon's Jamie Lazarovits on Unlocking the Full Power of Antibodies With AI</span></p></a></div></div></div></div></div></div></div><div class="iQxdxLc2HsEnJMZt0Us4"><hr class="HorizontalRule__HorizontalRuleElement-sc-198gjx4-0 gPhSUm bHqWsu7YPnOhoFVoWo1o" data-encore-id="horizontalRule"/></div></div></div><div class="LQ6Ss79CdgHw2ScSPflQ"></div></div></div></div><aside class="encore-dark-theme Yg_FlRTSnjxmfwyAvnFJ"><div></div></aside></div></div><script id="initial-state" type="text/plain">{"session":{"me":null,"product":{"country":"SG","catalogue":"premium","product":"PREMIUM","on-demand":"1"},"locale":"en","textDirectionality":"ltr","isAnonymous":true,"features":{"enableShows":true,"isTracingEnabled":false,"upgradeButton":"control","mwp":true,"isMWPErrorCodeEnabled":false,"isMwpRadioEntity":true,"isMWPAndPlaybackCapable":false,"preauthRecaptcha":false,"isEqualizerABEnabled":false,"isPodcastEnabled":true,"enableI18nLocales":true,"isI18nAdditionalPagesEnabled":false,"isInteractionLoggerEnabled":true,"isReinventFreeEnabled":false,"isEntityReportEnabled":true,"isAlbumReportEnabled":false,"isTrackReportEnabled":false,"isPodcastShowReportEnabled":false,"isPodcastEpisodeReportEnabled":false},"country":"SG","browserOS":"android","canGoBack":false,"canGoForward":false},"connect":{"device":null,"devices":[],"manualTransferDeviceId":null},"entities":{"items":{"spotify:episode:0BUwq1DLQg9KAFG1jaV4mC":{"__typename":"Episode","audio":{"items":[{"fileId":"c07e7b4c132905a323dd9370f9fa1e0b0767fd18","format":"OGG_VORBIS_96","url":"https://p.scdn.co/mp3-preview/c07e7b4c132905a323dd9370f9fa1e0b0767fd18"},{"fileId":"2367ff5d325ca4ff2626a1a1ab905f40883a081d","format":"MP4_128_DUAL","url":"https://p.scdn.co/mp3-preview/2367ff5d325ca4ff2626a1a1ab905f40883a081d"},{"fileId":"3e7b2f626eb3cce9a4e7b5007804e4fad7d38e78","format":"AAC_24","url":"https://p.scdn.co/mp3-preview/3e7b2f626eb3cce9a4e7b5007804e4fad7d38e78"},{"fileId":"5db1ba43101af8797d2a893dce6106b9ded45d29","format":"MP4_128","url":"https://p.scdn.co/mp3-preview/5db1ba43101af8797d2a893dce6106b9ded45d29"},{"fileId":"b87d1f6af797cb9c1b88756c06dbc7753d904c72","format":"MP4_128_CBCS","url":"https://p.scdn.co/mp3-preview/b87d1f6af797cb9c1b88756c06dbc7753d904c72"}]},"audioPreview":{"format":"MP3_96","url":"https://podz-content.spotifycdn.com/audio/clips/18Nn6VFMnXRGgN3BVvSQVa/clip_428102_488102.mp3"},"availableMarkets":{"items":[{"countryCode":"AD"},{"countryCode":"AE"},{"countryCode":"AG"},{"countryCode":"AL"},{"countryCode":"AM"},{"countryCode":"AO"},{"countryCode":"AR"},{"countryCode":"AT"},{"countryCode":"AU"},{"countryCode":"AZ"},{"countryCode":"BA"},{"countryCode":"BB"},{"countryCode":"BE"},{"countryCode":"BF"},{"countryCode":"BG"},{"countryCode":"BH"},{"countryCode":"BI"},{"countryCode":"BJ"},{"countryCode":"BN"},{"countryCode":"BO"},{"countryCode":"BR"},{"countryCode":"BS"},{"countryCode":"BT"},{"countryCode":"BW"},{"countryCode":"BZ"},{"countryCode":"CA"},{"countryCode":"CH"},{"countryCode":"CI"},{"countryCode":"CL"},{"countryCode":"CM"},{"countryCode":"CO"},{"countryCode":"CR"},{"countryCode":"CV"},{"countryCode":"CW"},{"countryCode":"CY"},{"countryCode":"CZ"},{"countryCode":"DE"},{"countryCode":"DJ"},{"countryCode":"DK"},{"countryCode":"DM"},{"countryCode":"DO"},{"countryCode":"DZ"},{"countryCode":"EC"},{"countryCode":"EE"},{"countryCode":"EG"},{"countryCode":"ES"},{"countryCode":"FI"},{"countryCode":"FJ"},{"countryCode":"FM"},{"countryCode":"FR"},{"countryCode":"GA"},{"countryCode":"GB"},{"countryCode":"GD"},{"countryCode":"GE"},{"countryCode":"GH"},{"countryCode":"GM"},{"countryCode":"GN"},{"countryCode":"GQ"},{"countryCode":"GR"},{"countryCode":"GT"},{"countryCode":"GW"},{"countryCode":"GY"},{"countryCode":"HK"},{"countryCode":"HN"},{"countryCode":"HR"},{"countryCode":"HT"},{"countryCode":"HU"},{"countryCode":"ID"},{"countryCode":"IE"},{"countryCode":"IL"},{"countryCode":"IN"},{"countryCode":"IS"},{"countryCode":"IT"},{"countryCode":"JM"},{"countryCode":"JO"},{"countryCode":"JP"},{"countryCode":"KE"},{"countryCode":"KH"},{"countryCode":"KI"},{"countryCode":"KM"},{"countryCode":"KN"},{"countryCode":"KR"},{"countryCode":"KW"},{"countryCode":"LA"},{"countryCode":"LB"},{"countryCode":"LC"},{"countryCode":"LI"},{"countryCode":"LR"},{"countryCode":"LS"},{"countryCode":"LT"},{"countryCode":"LU"},{"countryCode":"LV"},{"countryCode":"MA"},{"countryCode":"MC"},{"countryCode":"ME"},{"countryCode":"MG"},{"countryCode":"MH"},{"countryCode":"MK"},{"countryCode":"ML"},{"countryCode":"MN"},{"countryCode":"MO"},{"countryCode":"MR"},{"countryCode":"MT"},{"countryCode":"MU"},{"countryCode":"MV"},{"countryCode":"MW"},{"countryCode":"MX"},{"countryCode":"MY"},{"countryCode":"MZ"},{"countryCode":"NA"},{"countryCode":"NE"},{"countryCode":"NG"},{"countryCode":"NI"},{"countryCode":"NL"},{"countryCode":"NO"},{"countryCode":"NP"},{"countryCode":"NR"},{"countryCode":"NZ"},{"countryCode":"OM"},{"countryCode":"PA"},{"countryCode":"PE"},{"countryCode":"PG"},{"countryCode":"PH"},{"countryCode":"PL"},{"countryCode":"PR"},{"countryCode":"PS"},{"countryCode":"PT"},{"countryCode":"PW"},{"countryCode":"PY"},{"countryCode":"QA"},{"countryCode":"RO"},{"countryCode":"RS"},{"countryCode":"RW"},{"countryCode":"SA"},{"countryCode":"SB"},{"countryCode":"SC"},{"countryCode":"SE"},{"countryCode":"SG"},{"countryCode":"SI"},{"countryCode":"SK"},{"countryCode":"SL"},{"countryCode":"SM"},{"countryCode":"SN"},{"countryCode":"SR"},{"countryCode":"ST"},{"countryCode":"SV"},{"countryCode":"SZ"},{"countryCode":"TD"},{"countryCode":"TG"},{"countryCode":"TH"},{"countryCode":"TL"},{"countryCode":"TN"},{"countryCode":"TO"},{"countryCode":"TR"},{"countryCode":"TT"},{"countryCode":"TV"},{"countryCode":"TW"},{"countryCode":"TZ"},{"countryCode":"UA"},{"countryCode":"US"},{"countryCode":"UY"},{"countryCode":"UZ"},{"countryCode":"VC"},{"countryCode":"VN"},{"countryCode":"VU"},{"countryCode":"WS"},{"countryCode":"XK"},{"countryCode":"ZA"},{"countryCode":"ZM"},{"countryCode":"ZW"}]},"contentInformation":null,"contentRating":{"label":"NONE"},"coverArt":{"extractedColors":{"colorLight":{"blue":136,"green":121,"hex":"#6A7988","red":106}},"sources":[{"height":64,"url":"https://i.scdn.co/image/ab6765630000f68d47af993b6b750468dbd95041","width":64},{"height":300,"url":"https://i.scdn.co/image/ab67656300005f1f47af993b6b750468dbd95041","width":300},{"height":640,"url":"https://i.scdn.co/image/ab6765630000ba8a47af993b6b750468dbd95041","width":640}]},"description":" NCI SBIR Director Michael Weingarten and Rukiyah Van Dross-Anderson, Founder and CEO of SBIR-funded Claradele Pharmaceuticals discuss the journey from postdoc to biotech startup and how women and underrepresented entrepreneurs with innovative cancer solutions can also leverage SBIR support to move their ideas forward. Listen to this podcast to hear:  •               Stages of product development (fundraising rounds, company collaborations, team culture development, and more)  •               Lessons Learned when transitioning from academia to the early stages of product commercialization  •               Benefits of contacting program directors when applying for SBIR/STTR opportunities  •               Coaching received through the Applicant Assistance Program  •               Utilizing state biotech professional organizations  •               Programs early-stage businesses can use    Podcast Guest Speakers:     Name   Bios       Michael Weingarten, MA Director SBIR Development Center National Cancer Institute     In this role, Michael Weingarten leads a team of nine Program Directors who manage all aspects of the NCI SBIR & STTR Programs including a portfolio of $182M in grants and contracts annually. The SBIR & STTR programs are NCI's engine of innovation for developing and commercializing novel technologies and products to prevent, diagnose, and treat cancer. Weingarten has implemented a set of key initiatives for optimizing the performance of the NCI SBIR Program at the NIH. These include the establishment of a new model at the NCI for managing the program - the SBIR Development Center.             Rukiyah Van Dross-Anderson, PhD  Founder and CEO  Claradele Pharmaceuticals     Rukiyah T. Van Dross-Anderson, PhD is the CEO and founder of NCI SBIR-funded therapeutics company, Claradele Pharmaceuticals. Her work began at East Carolina University, where she is an associate professor and the director of Graduate Programs, Pharmacology & Toxicology Concentration. Dr. Van Dross-Anderson is working to develop an effective and non-toxic drug as an alternative therapeutic regimen for melanoma patients who aren’t responsive to traditional treatments.  To attract third-party investors that would help get her innovation to get to the patients that need them, Dr. Van Dross-Anderson is working through proof-of-concept studies to demonstrate her innovation’s commercial viability. Through her participation in the NCI SBIR program, she used funding to scale up production and received entrepreneurial mentorship to navigate the complex business world. Dr. Van Dross-Anderson graduated from Rutgers University, UMDNJ-RWJMS with a doctoral degree in Molecular and Cellular Pharmacology.       Programs referenced in this episode:  •               Minority Biomedical Research Symposium (MBRS) program - http://mbrs.newark.rutgers.edu/  •               Minority Access to Research Careers - https://www.nigms.nih.gov/training/MARC/Pages/USTARAwards.aspx  •               Applicant Assistance Program - https://sbir.cancer.gov/small-business-funding/application-process/applicant-assistance  •               I-Corps at NIH program - https://sbir.cancer.gov/commercialization/business/icorps  •               NCI SBIR Women’s Innovation Network  •               Office of technology transfer (offered at most school)  •               NCI SBIR Investor Initiative - https://sbir.cancer.gov/commercialization/business/investor-initiatives  •               Small Business Transition Grant - https://sbir.cancer.gov/small-business-funding/grants/small-business-transition Transcript:               KEY:     MICHAEL = Michael Weingarten,                   RUKIYAH = Dr. Rukiyah Van Dross-Anderson                    [music]                    MICHAEL: Hello and welcome to Innovation Lab, your go to resource for all things biotech startups, brought to you by the National Cancer Institute’s Small Business Innovation Research, SBIR Development Center.                    Our podcast hosts interviews with successful entrepreneurs and provides resources for small businesses looking to take their cutting edge cancer solutions from lab to market.                    I'm Michael Weingarten, the director of NCI SBIR and today's host. Today, in celebration of the Women's History Month, I'm excited to introduce our listeners to one of our women awardees, Dr. Rukiyah Van Dross-Anderson. Rukiyah is the CEO and founder of an NCI SBIR funded therapeutics company Claradele Pharmaceuticals. Her work began at East Carolina University where she is an associate professor and the Director of Graduate Programs, Pharmacology and Toxicology Concentration.                    Dr. Van Dross-Anderson is working to develop an effective and non-toxic drug as an alternative therapeutic regimen for melanoma patients who aren't responsive to traditional treatments. We will discuss her journey from post-doc to biotech startup, and share how women and underrepresented entrepreneurs with innovative cancer solutions can also leverage SBIR support to move their ideas forward. Welcome, Rukiyah.                    RUKIYAH: Thank you. Thank you for having me.                    MICHAEL: Can you kind of walk us through the arc of your career and how your company Claradele was formed?                    RUKIYAH: Oh, sure. So my research career began at Alabama State University, where I was a chemistry major, and through the university, I participated in some really important programs that helped me to understand that I really love research.                    So as an undergraduate, I was in the MBRS program, which stands for a Minority Biomedical Research Symposium. I was also a MARC student, Minority Access to Research Careers, and these two programs were NIH-funded programs that gave undergraduate students an opportunity to experience research.                    And it's through that experience that I found my true love, which is research. So after graduation from my undergraduate institution, I did two post-docs, one at Vanderbilt University and the other at the University of Kansas Medical Center. It was there that I honed my skills and really learned how to become a cancer researcher.                    From there I became part of the faculty at East Carolina University as an assistant professor, and I'm now an associate professor. And so throughout these years, I was really focused on developing novel agents that were effective against cancer. And so through this process, we discovered a novel molecule which we obtained a patent for to use as a therapeutic for melanoma and other types of cancer.                    And so thereafter the question was, what do we do next? What do we do with this molecule that we've patented and how do we get it to the stage where the public has access to it or the public can use this therapeutic? And so to kind of answer that question, I started attending different workshops that discuss the different options or the different ways in which drugs can be commercialized.                    And through this experience, I chose to form my biotech company, which is called Claradele Pharmaceuticals, and this company was founded in 2020.                    MICHAEL: Got it. So you've really had an interesting journey. You know, based on the research and then deciding to start Claradele. Can you maybe tell us a little bit more about the product and the technology that you've been working on, with funding that we've been providing from NCI SBIR?                    RUKIYAH: Sure. Yeah. So what we're working on is developing a small molecule therapeutic. And this agent has the ability to kill melanoma cancer cells and also stimulate the immune system. So the action of cancer killing and stimulating the immune system are really critical for effective tumor eradication.                            And our data, thus far, indicates that we have an agent with unique and promising properties that has the ability to eliminate cancer cells.                    MICHAEL: And can you maybe talk a little bit about how your approach and your solution are a little bit different from maybe what others are pursuing or what's currently available to patients?                    RUKIYAH: So current therapeutic agents are incredible. They're much more effective than agents that were available in the past. And so these remarkable agents have the ability to cure cancers in some settings. But the problem is, is that these amazing drugs are not effective in every patient.                    So what we want to do is to develop an agent that is effective against those resistant tumors, and so provide alternative therapies for people who are not responding to the current agents that are available.                    MICHAEL: Oh, that's really interesting. So are there specific types of melanoma that your research shows your drug is more effective against, whereas the current treatments aren't effective?                    RUKIYAH: Yes, our research thus far is showing that when we use a model, that is resistant to the current therapies, our drug can work in that resistant model. In addition, we're also finding that we can help the drugs that are already available to be even more effective.                    So we're looking at our drug as a single agent and also combined with other agents to see where is our niche, where does our drug work best?                    In addition, in our future studies, we plan to test other types of melanoma, those rare melanomas to which therapeutics that are currently available are not effective, so we can foresee using this agent in the treatment of different types of melanoma.                    MICHAEL: So that's really interesting. You're kind of pursuing both the single agent approach, where you would be the primary treatment for the melanoma, but you're also looking at combination therapies. I'm curious, are you collaborating with any other companies that are also in the same space? And does it look like your drug is complimentary to their drug?                    RUKIYAH: Yes, so that's one of our next steps. We're working to identify companies that we can work with in order to do that testing. And we plan to try to use both of those agents together, yes.                    MICHAEL: And so what stage are you, are you at now? Have you optimized your leads or are you into IND enabling studies?                    RUKIYAH: So right now we're in the stage, we're in the middle of doing our proof of concept studies. And our goal here is to find out the best way to administer the drug, under which circumstances. And we also want to identify the types of tumors to which our drug responds the most effectively.                    And so, we are now approaching the stage where we're going to begin a fundraising round. And with that fundraising, what we plan to do is to use those dollars in order to fund the regulatory studies that we need to prepare for that IND meeting.                    MICHAEL: Can you maybe talk a little bit about how you think your team is uniquely positioned to succeed in terms of developing the drug? And you know, it's a long path to get a drug from the very earliest stages, where you are, all the way into the clinic, treating patients, and then ultimately out to patients and getting FDA approval. How is your team uniquely positioned to succeed, do you feel?                    RUKIYAH: You know, our team is composed of individuals who are experts in their field. We are constantly evaluating and modifying our team to make sure that we have the expertise on board when we need it.                    And so I believe, though, that our special formula is that several members on our team have a personal cancer story, and that personal cancer story helps us to stay motivated, and it helps us to use that experience, plus our talents, to keep driving this process forward.                    And you know, most people have a cancer story. And you know, to be able to use that as your passion and your motivation, to make sure that you do your best to move it forward, is the unique part of our team because most of us do have that experience.                    MICHAEL: Yeah. No, I think you guys bring a really unique perspective with that. And I agree with you, as a cancer survivor, that does provide a very special motivation and a connection with cancer patients too. Rukiyah, maybe you could also talk a little bit about your, you know, your process for applying for your NCI SBIR award. You know, did you interact with an SBIR program director before you applied? And if you did, how did that help, help you out?                    RUKIYAH: So I submitted an application for the SBIR STTR several times before it was actually funded. And I will say that in the beginning, for my first couple of submissions, I did not interact with the program director. However, on the later stages, I began interacting with the program director.                    And one of the reasons that I didn't interact with the program director initially was that I kind of felt like it might be wasting their time. I didn't want to bother them, and I was concerned that if I asked the wrong question, it might appear that I was not ready for this opportunity.                    So I chose not to do it, but that was not really the best way to go, because as I mentioned in my later submissions, I started interacting with the program officers and I can tell you it made all of the difference in the world.                    The program directors, you are not wasting their time when you call them, set up an appointment, you're not wasting their time at all. And they're very friendly, they're very helpful, and I can tell you, I learned so much from interacting with them that it really made the difference in getting that application funded.                    And so, you know, in interacting with the program directors, they gave you, they'll give you lots of helpful information. You may ask a question and you may think that you know the answer to it, but there may be more to it, and they can give you more insight into, you know, why a particular situation may be important. They may open up some other opportunities that you were not aware of, so very, very helpful to interact with your program officers.                    And I can say, in my experience, I've had wonderful program officers, like Billy Bozza, who is wonderful. And I can tell you that the most important interaction that I had, as I mentioned, I submitted my application several times, and I was at the stage where I was going to give up and I wasn't going to resubmit again. And I can tell you that he told me “Don't give up. Let's try again, you’re this close. Let's try it again and see what happens.”                    And he gave me advice that I needed to, to really focus on those issues that the reviewers thought needed to be bolstered, and again, it made all of the difference in the world.                    So interacting with your program officers can make the difference between getting the application funded and not getting it funded, part of what they do is to help you to get your proposal funded.                    MICHAEL: Yeah. No, that's really valuable feedback. And we, we actually spend probably at least a third of our time interacting with, with applicants like yourself, because it can be a really, if you haven't applied for an SBIR grant at the NIH, you know, it can seem like a tall hill to climb sometimes, but our programs there, our program directors are there to help kind of smooth things over, explain the process, explain the different parts of the application, and really advise overall on what the NIH peer reviewers tend to look for in a strong proposal.                    So we actually think that's one of the most important parts of our jobs is interacting with applicants like yourself and others, and really trying to demystify the process and making it easier too. So it's really helpful to hear that back.                    Now, did you also participate in the Applicant Assistance Program and, and if so, how did that kind of change the way you approached the application process?                    RUKIYAH: Yes, I did participate in the Applicant Assistant Program and again, it was a great program. It really helped me to compose an application that was fundable.                    So I'll start by saying that both me and my institution have limited experience with the SBIR/STTR Grant. So because of this, I had no mentorship. I didn't really know how to put this grant together because it's very different from a traditional R grant.                    And so, without that mentorship, you know, I would compose it, submit it, and you know, that's how I would get my feedback as to how to put this together. So then by participating in the AAP, the people who are administering that program have extensive experience putting these types of grants together, and so they really helped me, provided me with the guidance that I need to put a fundable application together.                    So for example, they helped me to understand what was allowable in terms of a company budget. We know as academics what's allowable as, on the budget, but on the company side it's a little bit different, so they help me to bridge my understanding of the company and the academic setting so that the budget would be set up properly.                    Another example, they helped me with other aspects of the sheets of the different forms that needed to be filled out dealing with the company side of this whole process. And they also helped me to understand what are the expectations or the most likely expectations of the reviewers.                    Again, the reviewer board is composed not only of scientists, but people who are business people, and I have no formal business training, so that helped me a lot to really refocus and think about what is expected in that grant, and the people in the AAP program helped me to understand that.                    And so also another really important thing, as we were going through this process, the program will put you on a schedule. And so with that schedule, you have deadlines and milestones, and you complete these things on time so that the package is ready well in advance of the deadline, and this is really important because we all know when you wait till the last minute, it’s really difficult to put in a good package.                        And so by setting up those deadlines, it really helped me to be able to compose it and then to be able to come back and look at it later, with a fresh mind and fresh thoughts. And so the AAP program was really, really helpful and I highly recommend it.                    MICHAEL: That's -- I think that's really valuable feedback to our listeners today. We set up the AAP program about five years ago and it really is -- it was set up to do the exactly the things that you described, which is taking applicants, as they're putting together their, their applications, and really kind of coaching them, providing a coach who can kind of guide them through the whole application process.                    I've heard from a number of companies who have gone through AAP, like yourself, that it really did help them prepare to get an award. Sometimes they had applied in the past, like, like you had, and had not been successful. But then when they went through AAP and then they, they resubmitted their proposals and they learned, you know, from the coach who was kind of guiding them, they got stronger scores when they reapplied like you did, and then we were able to give them an award, because they had strengthened their application.                    So that that's the whole goal of the Applicant Assistance Program, and for those who are interested, we're actually going to be putting on a webinar on April the 25th, talking about the Applicant Assistance Program. And you can sign up and apply to participate in, in the AAP program. So April 25th is the next date for the webinar, I encourage folks to attend that. And you can also go to our website at sbir.cancer.gov and get more information about the Applicant Assistance Program there.                    OK, moving on just a little bit, you have a background that is very similar to what our, a lot of our applicants are experiencing when they're first getting involved in SBIR, and that you come from an academic background and you were working to start up your company, I'm sure there are a lot of challenges involved in that, because, you know, you're, you're an academic by training, you were not an entrepreneur.                    So you've had to kind of learn that along the way. So maybe it would, it would be really useful to our listeners, could you maybe talk a little bit about some of the key lessons learned as you've gone through your commercialization journey? And were there -- Was there any, any coursework, like, for example, the I-Corps program that you were able to tap into in order to give you the kind of information you needed to help as you were building your company?                    RUKIYAH: So yes, key lessons learned. I learned a lot of lessons in developing a company. As I mentioned, I have no formal business training, but what I did to kind of understand the basics of business is to attend lots of different workshops. Those workshops provided me with some information about business, about drug development.                    And then, what I started doing is to partner with people who are experts, so I don't have to be the business professional. But what my goal is, is to learn enough about business to understand with the business partners are talking about, and also to be able to contribute to the decision making process.                        And so that's my goal with learning about business, and I use the skills that we use as academics all the time and collaborate. Collaborate, bring people in who have the expertise that you need, rather than trying to be a professional or to be in a position that you really don't have the qualifications for. And so that's been my approach for making this happen.                    And so another thing that I've learned about business is that business is quite different from academia. In academia, we plan, we, we aim for perfection, and we have a route, and we try to stay with it and pivot when the science takes us there.                    In the business world, it’s a lot different. And I think the general mentality is that you are going to make mistakes. And so as, as was mentioned, you know business is new for me. So I've made mistakes and the idea is mistakes are expected. And when you make those mistakes, you just pick up and keep moving forward.                    The key is to have people around you who understand the business and know how to mitigate those mistakes and keep moving forward.                    MICHAEL: Yeah, I think those are, those are excellent lessons. There, there is a program, in addition to the valuable training that you were able to seek out in the -- and the mentors you were able to seek out on your own, NIH also offers a program called Innovation Corps or I-Corps, and it's open right now to companies that have an SBIR at the NIH, whether it's at NCI or a different institute.                    And it's really kind of like a boot camp to help companies learn how to put together a business strategy around the technology that they're developing.                    So it's a 10 week program we bring in instructors who are experts in areas like therapeutics, devices, diagnostics, and they are there to help guide the participants in going through that program. We have found that I-Corps has really helped launch a lot of our companies and really advanced through the development process. And it really does that through companies learning what the value proposition, and where their, where their technology can really make an impact and solve an unmet need. So I encourage folks to go up on our website and look for information about I-Corps program, I-C-O-R-P-S.                    RUKIYAH: So you're absolutely correct. The I-Corps is a wonderful program. I also participated in this program as well and it helped me to identify the specific niche of my product. So where does your product fit in this vast market of products that offer to do similar things?                    So I-Corps is really important to help you really fine tune your commercialization plan. And you know, I've also participated in other programs that I think are really, really important. For example, the SBIR-STTR workshops and road shows, man, those are some great programs.                    And I'll say that I've attended these programs over and over again because each time that I go or I participate, I learn something new. And it reminds you of all of the options that are available to really push your product forward. So it's a great idea to really attend these workshops and pick up as much knowledge as you can in order to push, push your technology forward.                    Also, once your grant is funded, I would like to recommend the Women's Innovation Network or WIN. That's a great program. It provides a supportive community of female SBIR-STTR recipients. It provides mentoring. We have speakers who talk about different aspects of commercialization, and it provides an opportunity for female investigators to network with each other, and to be a little vulnerable. And by being vulnerable, we can help each other, and so I recommend that as well.                    I'd also like to recommend, for those who are seeking to develop a business, a biotechnology business for their laboratory discoveries, you may have some local resources that you can tap into. Many states have different biotechnology professional organizations that put on workshops and they -- some provide funding. And they provide different types of education about entrepreneurship.                        So there may be some local organizations that you can also take part in, in order to learn, to build your business. And I would probably start to find out about if your state has a similar organization. Maybe start in your office of technology transfer, because that's the location where, in academia, that's kind of the line between academia and the commercial environment. So I would start there to find out if there are some local organizations that can also help you to get where you need to go.                    MICHAEL: Yeah. And really thanks so much for bringing some of these programs up. Rukiyah. One of the things that I like to talk about, when I talk about our SBIR program is, I think people understand that SBIR provides funding, which is obviously the most critical element.                    The way I like to think of it is it's necessary, obviously, but it's not sufficient. You know, you’re small business, you need funding obviously, but you need access to a whole range of different resources in addition to funding. So that's one of the things that separates the NCI SBIR program, I think, from others in that we really put a lot of time into thinking about and creating resource programs that our companies need.                    So just as an example, you mentioned I-Corps, that was one program we created here at NCI SBIR for the NIH as a whole. But we also offer our Investor Initiatives Program, too, where we are able to connect companies that we're funding through our SBIR program with private investors.                    So that, you know, as you're developing your drug, you're in the earlier stages now, you're obviously going to need to go out and raise additional capital. Because we're the NCI, we're able to develop relationships with some of the largest investors around the country, whether that's large pharmaceutical companies or some of the large venture capital funds around the country that invest in the cancer space.                    So once a year, we invite all the companies that we are funding in our portfolio to go through our Investor Initiatives Program. And that's an opportunity for you to put together a short application, which will then be reviewed by a panel of investors.                    And then those investors help us identify companies that are ready to go out and present and pitch their technology to, to other investors in order to help raise capital. And then we also do pitch coaching, to help, to help prepare our companies to, to go out and present.                    RUKIYAH: I can say that that's really important because in this current climate, it's very difficult to raise funds. So having that edge, having those connections would be very helpful.                    MICHAEL: I was wondering, maybe you could provide some advice. You mentioned the WIN Program as an example, you know, a program that we offer to women entrepreneurs in our program, and give them the opportunity to come together and really kind of share lessons learned.                    In addition to that, do you have any other advice for women in academia who want to transfer their technology and really kind of start that journey towards a start up?                    RUKIYAH: Sure. You know, the first thing that I would say is that this is very doable. It's doable because women have some ingrained properties that are really conducive to making this happen. For example, our ability to multitask is very important and very critical for getting this job done.                    And so the job of transferring the technology into the commercial space takes a lot of multitasking. You can work with different people in order to get things done. Collaboration, that's also another property that we have as academics, and so we can collaborate with people in order to get things done.                    And so for me personally, one of the things that I had to resist was the urge to be Superwoman. And so for me, what I usually try to do is do everything myself and, you know, try to achieve it all by myself, and that's really not the way to go.                    What you - What is successful is to collaborate and delegate in order to achieve your goals. So that's one of the things that I would say that we really have to do as women, collaborate, don't try to do it all, find the experts and let the experts do what they know how to do.                    And then finally, I would say in terms of advice for women, I would say ask for what you want. Sometimes we don't like to ask and -- ask people for help or ask for resources, but you have to ask, all, all that can be said is either yes or no. So just ask and if the answer is no, try another route and keep moving forward. Don't take it personally, just keep moving forward.                    MICHAEL: I really think that's -- I think -- I really think that's excellent advice. There's, there's another program really focusing on academics doing the research, developing a technology who are interested in making that transition. There's another program that we offer called the Small Business Transition Grant.                    It's a fairly new program, not a lot of folks are, are aware of it, but we're really trying to, to increase the awareness of that program and that, that program, we actually developed in response to conversations we were having with our cancer centers from across the country, where we were trying to figure out what can the NCI do to facilitate the translation of academic technologies and to get more technologies out of the lab and into small companies.                    And one of the key funding gaps that they told us was existing, was that it was really hard for early career academics, like post-docs, to raise funds. You know, there was kind of a dearth of funding when, when you're really at the early stages in your career trying to raise funding.                    So the Small Business Transition Grant actually is focused on, on post-docs and other early career academics, and it will provide funding to them while they're still at the university, both for their research as well as funding for both a technical mentor and a business mentor.                    And the whole goal is to provide kind of the, the support that that early-career academic needs, you know, sounds -- and it sounds like you were kind of in that same situation, but the goal is to provide funding as well as mentorship support to that early-career academic to help them as they're looking to move their technology out of a university to a small business.                    You can apply for either just a Phase 1 application or you can go for a combined Phase 1/Phase 2 application. And the funding will support the academic, first at the university, and then as they move their technology to a company, and they move -- and they advance that technology to a Phase 2, it'll continue that same support.                    So, it's another program that we have tried to tailor to the needs of you and other academics that are out there looking to apply. And, again, we have information about the Small Business Transition Grant up on our website at sbir.cancer.gov.                    We're actually going to be launching that program for the coming year sometime in, in March. So if you're interested in that, and I encourage everyone to, again, go up on our website to get more information and talk to a program director, reach out to us, send us an e-mail, and we're happy to give you more information about that program.                    RUKIYAH: Sounds like a really interesting project. I think it's a great idea because young -- Generation Z, Young investigators, they want to own businesses, a very different mentality from previous generations. So this type of program sounds like it would be really great to help to launch their ideas and their businesses in the biotech space.                    MICHAEL: Absolutely. And that's what we're trying to do with that, that program right now. It's, again, it's still a fairly young program, so we're, we're trying to, we're trying to talk about it a little bit more with folks like yourself to just kind of raise visibility that that's, that's a funding opportunity that an academic who's interested in moving to a small business, maybe creating their own small business, it's a funding opportunity that's, that's available to help to, to help support them on that.                    Well, this has been great. I've really enjoyed our conversation. I wanted to ask you just one last question, and that's, is there one piece of advice that you'd like to leave folks with before we leave today regarding, you know, your journey or their journey as they're looking to start it?                    RUKIYAH: Sure. I would say the best piece of advice that I can give is to use your skills that you have acquired as an academic researcher to start and grow your company. The skills that are necessary to make this work include: collaboration, persistence. You have to be persistent, networking. And so you can also use your passion, what is it that you really feel passionate about in order to keep the process moving forward?                    And then I would also advise you to take advantage of the resources that are available to help you with commercialization of biotechnology products. I would also say, as you mentioned, this is a very long drawn out process. So I would advise you to know what the process is, but don't focus on the big picture, focus on your milestones, because if you get focused on how big this whole process is, it's discouraging, right, and it may prevent you from moving forward.                    So just break your process up into milestones, achieve your next milestone, and, and view it from that perspective, rather than being focused on all that needs to be done. And I think that that has been really helpful to me to just kind of take this at small pieces.                    MICHAEL: Excellent advice, break it down step-by-step and if you can work on it step-by-step, then it's not such an overwhelming kind of thing, you know, set your goals, achieve that one goal, and move to the next one.                    Well, this has been wonderful. I've really enjoyed our conversation today. Thank you for taking the time. And I know it's going to be really valuable to a lot of the folks out in the community who are interested in coming back and applying for NCI SBIR. We look forward to working together with you in the future. And again, thank you.                    RUKIYAH: Thank you so much for inviting me to talk. I hope that some of the information that I've shared will be helpful to someone. And it is great to be part of a community of people who are really devoted to developing cancer chemotherapeutics. And again, I just thank you for the invitation.                    MICHAEL: Thank you. Thanks so much Rukiyah for speaking with us today. We really look forward to seeing Claradele’s continued growth and making positive patient impact. As always, don't forget to check out our website, sbir.cancer.gov, for the latest funding opportunities and commercialization resources to support your journey from lab to market.                    This was Michael Weingarten from NCI SBIR. Please join us again for the next installment of NCI SBIR Innovation Lab and subscribe today wherever you listen.                    If you have questions about cancer or comments about this podcast, e-mail us at nciinfo@nih.gov or call us at 1-800-422-6237 and please be sure to mention Innovation Lab in your query.                    We are a production of the US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Thanks so much for listening.                    [music]      END OF FILE    ","duration":{"totalMilliseconds":2372591},"htmlDescription":"","id":"0BUwq1DLQg9KAFG1jaV4mC","language":{"code":"en"},"mediaTypes":["AUDIO"],"name":"Episode 6. Entrepreneur Spotlight: Rukiyah Van Dross-Anderson, Claradele Pharmaceuticals","playability":{"playable":true,"reason":"PLAYABLE"},"playedState":{"playPositionMilliseconds":0,"state":"NOT_STARTED"},"showOrAudiobook":{"__typename":"PodcastResponseWrapper","data":{"__typename":"Podcast","accessInfo":null,"contentRating":{"label":"NONE"},"coverArt":{"sources":[{"height":64,"url":"https://i.scdn.co/image/ab6765630000f68d47af993b6b750468dbd95041","width":64},{"height":300,"url":"https://i.scdn.co/image/ab67656300005f1f47af993b6b750468dbd95041","width":300},{"height":640,"url":"https://i.scdn.co/image/ab6765630000ba8a47af993b6b750468dbd95041","width":640}]},"description":"Welcome to Innovation Lab, your go-to resource for all things biotech startups, brought to you by the National Cancer Institute's (NCI) Small Business Innovation Research (SBIR) Development Center.","id":"4ZgsJahci1QqCScnHHZjEZ","mediaType":"AUDIO","name":"SBIR Innovation Lab","playability":{"playable":true,"reason":"PLAYABLE"},"publisher":{"name":"National Cancer Institute"},"saved":false,"showTypes":[],"trailerV2":{"data":{"audio":{"items":[{"url":"https://p.scdn.co/mp3-preview/0c546ff05b5408db075e3de9a6d850d4a0496c50"},{"url":"https://p.scdn.co/mp3-preview/d929a18b6b81e7196d7945ba131f4b131f772432"},{"url":"https://p.scdn.co/mp3-preview/c9766c2ff2385ffaa98deb01205e2dd701b64c6f"},{"url":"https://p.scdn.co/mp3-preview/4c59ada296355710b844a68a1207c3d076819951"},{"url":"https://p.scdn.co/mp3-preview/c531a4c7e6d86239af3608374897ccfd780e9a3e"}]},"audioPreview":{"url":"https://podz-content.spotifycdn.com/audio/clips/5brmkl7pMcLLQTB1TeyolS/clip_17468_77468.mp3"},"contentRating":{"label":"NONE"},"duration":{"totalMilliseconds":80100},"name":"Teaser. Get Ready to Advance from Lab to Market!","playability":{"playable":true,"reason":"PLAYABLE"},"releaseDate":{"isoString":"2023-11-29T15:37:00Z"},"uri":"spotify:episode:1mHHsEcskAAZRpngrhbmAx"}},"uri":"spotify:show:4ZgsJahci1QqCScnHHZjEZ"}},"preview":{"audio":{"url":"https://podz-content.spotifycdn.com/audio/clips/18Nn6VFMnXRGgN3BVvSQVa/clip_428102_488102.mp3"},"shareable":true,"video":{"url":""}},"releaseDate":{"day":20,"isoString":"2024-03-20T08:00:00Z","month":3,"precision":"MINUTE","year":2024},"type":"PODCAST_EPISODE","uri":"spotify:episode:0BUwq1DLQg9KAFG1jaV4mC"}},"recommendations":{},"saved":{}},"playback":{"current":null,"hasSkippedThisSession":false,"isBuffering":false,"heardAudio":false,"initiatedPlayback":false},"request":{"hasPreviousLikes":false,"isBanned":false,"entityView":null,"albumUri":""},"search":{"isFetching":false,"results":null,"query":null,"error":null,"recentSearches":[]},"toast":{"message":null,"type":"default","action":null},"ui":{"modal":"now_playing_bar","nowPlayingView":false,"dialog":null,"errorView":false},"home":{"isLoading":false,"hasError":false,"data":null},"onDemandPlaylists":{"fetched":false,"items":[]},"contextMenu":{"isVisible":false},"colorExtraction":{"colors":{}},"lyrics":{"status":"UNAVAILABLE"},"richEntities":{"seoExperiment":{"episode":{}}},"browse":{"grid":{"isLoading":false,"sections":null,"hasFailedAttempts":false},"pages":{}},"internalLinkRecommender":{"tracks":{"status":"UNAVAILABLE"},"shows":{"status":"UNAVAILABLE"},"episodes":{"data":[{"__typename":"Episode","audio":{"items":[{"fileId":"ed2cdf697dbb4dbf39361a8979963997fb05748a","format":"OGG_VORBIS_96","url":"https://p.scdn.co/mp3-preview/ed2cdf697dbb4dbf39361a8979963997fb05748a"},{"fileId":"659f1860ff341eb568f3dd06bfc383e1d94074f2","format":"AAC_24","url":"https://p.scdn.co/mp3-preview/659f1860ff341eb568f3dd06bfc383e1d94074f2"},{"fileId":"d0eddd30f110ca2bc5c64f0399f3deff1d361f5c","format":"MP4_128_DUAL","url":"https://p.scdn.co/mp3-preview/d0eddd30f110ca2bc5c64f0399f3deff1d361f5c"},{"fileId":"d59a45bd202c74e619c7b9909d126a872452a77a","format":"MP4_128_CBCS","url":"https://p.scdn.co/mp3-preview/d59a45bd202c74e619c7b9909d126a872452a77a"},{"fileId":"9d7c16bfeaee8fad33a1373b9f24e54e7c2709fa","format":"MP4_128","url":"https://p.scdn.co/mp3-preview/9d7c16bfeaee8fad33a1373b9f24e54e7c2709fa"}]},"contentRating":{"label":"NONE"},"coverArt":{"sources":[{"height":64,"url":"https://i.scdn.co/image/ab6765630000f68dc0a9253195bd0eaeaf5c5a17","width":64},{"height":300,"url":"https://i.scdn.co/image/ab67656300005f1fc0a9253195bd0eaeaf5c5a17","width":300},{"height":640,"url":"https://i.scdn.co/image/ab6765630000ba8ac0a9253195bd0eaeaf5c5a17","width":640}]},"description":"Synopsis:   In this episode of BioTech 2050, Ken Keller, President and CEO of Daiichi Sankyo, Inc. provides an in-depth look into the company's transformation from a cardiovascular-focused organization to a leader in oncology. He discusses the groundbreaking advancements in antibody-drug conjugates (ADCs), particularly highlighting the success of their HER2-targeted therapies. Ken shares his career journey, emphasizing the importance of building a team of passionate individuals who are eager to innovate and make a difference. He also touches on the significance of strategic partnerships in accelerating drug development and ensuring global access to life-saving treatments. The conversation offers valuable insights into the future of cancer therapies and the dynamic landscape of the biotech industry.   Biography:  Ken Keller is the Chairman of the Board, President, and Chief Executive Officer of Daiichi Sankyo, Inc. He is also the Head of the Global Oncology Business responsible for leading the overarching company strategy of ensuring innovative medicines are available to patients with cancer around the world. With more than 30 years of experience in the pharmaceutical industry, Ken has led multi-billion dollar businesses in both U.S. and Europe while working to unify cross-functional teams to create a global infrastructure – enabling the commercial success of Daiichi Sankyo oncology and specialty medicines.  Through leadership roles in multiple markets, across cultures and within different healthcare systems, Ken has successfully launched numerous biologic products in therapeutic areas ranging from oncology to bone health to nephrology to inflammatory diseases, transformed businesses, and delivered sustainable revenue and profit growth. With more than 20 years of oncology experience, Ken had a longstanding career at Amgen where he held several leadership roles, with increasing global and commercial responsibility, including Vice President and General Manager, Bone Health Business Unit. Prior to joining Daiichi Sankyo, Ken served as Chief Operating Officer at Spectrum Pharmaceuticals, where he held global responsibility for leading commercial operations, medical and clinical development, regulatory, quality, safety and pharmaceutical operations. Ken is motivated by passion for innovation and compassion for patients, which is at the core of everything he instills within his leadership teams. Developing and coaching high-performing global teams that can have a profound impact on patient lives and leading an organization that is responsible for helping to change the standard of care for the oncology community is a privilege he is incredibly grateful for.","duration":{"totalMilliseconds":1698194},"id":"2HhhtyW30bgqD5TO2pLJyS","mediaTypes":["AUDIO"],"name":"Transformative Oncology Innovations, Ken Keller, President & CEO, Daiichi Sankyo, Inc.","playability":{"playable":true,"reason":"PLAYABLE"},"playedState":{"playPositionMilliseconds":0,"state":"NOT_STARTED"},"podcastV2":{"__typename":"PodcastResponseWrapper","data":{"__typename":"Podcast","coverArt":{"sources":[{"height":64,"url":"https://i.scdn.co/image/ab6765630000f68d338485a397063f5252371afc","width":64},{"height":300,"url":"https://i.scdn.co/image/ab67656300005f1f338485a397063f5252371afc","width":300},{"height":640,"url":"https://i.scdn.co/image/ab6765630000ba8a338485a397063f5252371afc","width":640}]},"name":"Biotech 2050 Podcast","showTypes":[],"uri":"spotify:show:64MEkVKtn8v1prQRgRzHyU"}},"releaseDate":{"isoString":"2024-06-06T13:00:00Z"},"restrictions":{"paywallContent":false},"uri":"spotify:episode:2HhhtyW30bgqD5TO2pLJyS"},{"__typename":"Episode","audio":{"items":[{"fileId":"7ae70069c44e3838f7dff0c80222e6da579b8921","format":"MP4_128","url":"https://p.scdn.co/mp3-preview/7ae70069c44e3838f7dff0c80222e6da579b8921"},{"fileId":"41fa404a1a497a91ee3bdda527c8c4efbd6ec849","format":"AAC_24","url":"https://p.scdn.co/mp3-preview/41fa404a1a497a91ee3bdda527c8c4efbd6ec849"},{"fileId":"161a9b9a4acb94b43d2d52b62d036925b391519e","format":"OGG_VORBIS_96","url":"https://p.scdn.co/mp3-preview/161a9b9a4acb94b43d2d52b62d036925b391519e"},{"fileId":"6d1129089f542143e2e4880ad433deaac37f24da","format":"MP4_128_CBCS","url":"https://p.scdn.co/mp3-preview/6d1129089f542143e2e4880ad433deaac37f24da"},{"fileId":"bf29d4cb59457f0a4f0e2f6c588e1077f5b95b91","format":"MP4_128_DUAL","url":"https://p.scdn.co/mp3-preview/bf29d4cb59457f0a4f0e2f6c588e1077f5b95b91"}]},"contentRating":{"label":"NONE"},"coverArt":{"sources":[{"height":64,"url":"https://i.scdn.co/image/ab6765630000f68d3775f82afc0f0aa51bd7b50b","width":64},{"height":300,"url":"https://i.scdn.co/image/ab67656300005f1f3775f82afc0f0aa51bd7b50b","width":300},{"height":640,"url":"https://i.scdn.co/image/ab6765630000ba8a3775f82afc0f0aa51bd7b50b","width":640}]},"description":"This is Zack Fuss, an investor at Irenic Capital. Today, we're breaking down Argenx, an immunology company founded in 2008 by its three founding partners. Today, it's a $30 billion company set to produce over a billion dollars in sales. They're known for their skill in developing antibodies for complex disease targets and owe a large part of their medical breakthroughs to llamas, which have similar antibodies in their immune system to those found in humans.  To break down Argenx, I'm joined by Julia Angeles, an investment manager at Baillie Gifford. Throughout this conversation, we'll discuss how Argenx navigates the complex world of drug development, clinical trials, regulatory approvals, and the ultimate commercialization of autoimmune therapies. We'll also learn more about their transition from a venture capital backed business to its 2017 IPO, and today, a meaningful revenue generating business. We hope you enjoy this business breakdown.  Note: This conversation was recorded on 19 July 2023.  For the full show notes, transcript, and links to the best content to learn more, check out the episode page here.   -----  This episode is brought to you by Tegus, the modern research platform for leading investors. Stretch your research budget with flexible expert calls you can trust. At a fraction of the cost of traditional expert networks, Tegus customers pay only what an expert charges – with zero markups and no confusing call credits – netting an average 70% savings. Don’t want to conduct a full hour call? Tegus offers the ability to schedule 30-minutes, an offer you won’t find anywhere else. And they don’t stop there. With white-glove custom sourcing for every project and robust compliance measures, including a dedicated 50+ analyst team that vets every call transcript, Tegus ensures your privacy and protection. As the industry innovator for qualitative insights, Tegus helps you find the right experts you need at a quality and speed that can’t be matched. For a limited time, as a listener, you can trial Tegus for free by visiting tegus.co/patrick.  -----  Business Breakdowns is a property of Colossus, LLC. For more episodes of Business Breakdowns, visit joincolossus.com/episodes.  Stay up to date on all our podcasts by signing up to Colossus Weekly, our quick dive every Sunday highlighting the top business and investing concepts from our podcasts and the best of what we read that week. Sign up here.  Follow us on Twitter: @JoinColossus | @patrick_oshag | @jspujji | @zbfuss | @ReustleMatt | @domcooke  Shownotes (00:03:49) - (First question) - Ways the immune system protects us and fails us (00:06:00) - Current patient treatments and evolving solutions to existing problems  (00:07:52) - The key difference between how the biotech community is addressing big diseases versus autoimmune disorders (00:09:55) - What sparked Julia’s interest in Argenx (00:14:01) - Explanation how we use animal antibodies to help research progression (00:15:25) - The foundations of the business (00:17:57) - The evolution of the business and its commercial success thus far (00:20:22) - Transitioning from lab antibodies to a commercial product ready for consumers (00:23:42) - The infrastructure needed to maintain and grow Argenx (00:26:43) - Indicators of commercial success (00:29:27) - The basic revenue model for this business type (00:30:49) - Go to market strategies for developed drugs  (00:34:39) - Pricing and patient protection of these newly developed drugs  (00:37:46) - Cures versus creating treatments with recurring revenue streams (00:39:38) - The importance of the current team composition  (00:41:44) - Julia’s perspective on what they are willing to invest to grow the company (00:43:49) - Normalized profitability for biotech companies such as this (00:45:59) - Potential risks to the current business model (00:49:22) - Lessons learned from studying Argenx","duration":{"totalMilliseconds":2661773},"id":"4RNuf1UccxAPr5Z1y5B3UM","mediaTypes":["AUDIO"],"name":"Argenx: Changing Lives with Llamas - [Business Breakdowns, EP.122]","playability":{"playable":true,"reason":"PLAYABLE"},"playedState":{"playPositionMilliseconds":0,"state":"NOT_STARTED"},"podcastV2":{"__typename":"PodcastResponseWrapper","data":{"__typename":"Podcast","coverArt":{"sources":[{"height":64,"url":"https://i.scdn.co/image/ab6765630000f68dcc2f439d01744fdd144a33de","width":64},{"height":300,"url":"https://i.scdn.co/image/ab67656300005f1fcc2f439d01744fdd144a33de","width":300},{"height":640,"url":"https://i.scdn.co/image/ab6765630000ba8acc2f439d01744fdd144a33de","width":640}]},"name":"Business Breakdowns","showTypes":[],"uri":"spotify:show:417NPBWqtMbDU0FlWZTRDC"}},"releaseDate":{"isoString":"2023-08-02T08:00:00Z"},"restrictions":{"paywallContent":false},"uri":"spotify:episode:4RNuf1UccxAPr5Z1y5B3UM"},{"__typename":"Episode","audio":{"items":[{"fileId":"6d25cb953086e71010c4892e77de65c27930d093","format":"AAC_24","url":"https://p.scdn.co/mp3-preview/6d25cb953086e71010c4892e77de65c27930d093"},{"fileId":"85aff50e7899322d937baa873853a56177ff972d","format":"MP4_128_DUAL","url":"https://p.scdn.co/mp3-preview/85aff50e7899322d937baa873853a56177ff972d"},{"fileId":"76ecdd873f62eb3e2402f45d595a5531cb85ae92","format":"MP4_128","url":"https://p.scdn.co/mp3-preview/76ecdd873f62eb3e2402f45d595a5531cb85ae92"},{"fileId":"3f42864ed3c799bc6285ec7e4408cbf1b709d731","format":"MP4_128_CBCS","url":"https://p.scdn.co/mp3-preview/3f42864ed3c799bc6285ec7e4408cbf1b709d731"},{"fileId":"b1cf1f56ae7cb6fd6bdd394d9d658b37d06ad36e","format":"OGG_VORBIS_96","url":"https://p.scdn.co/mp3-preview/b1cf1f56ae7cb6fd6bdd394d9d658b37d06ad36e"}]},"contentRating":{"label":"NONE"},"coverArt":{"sources":[{"height":64,"url":"https://i.scdn.co/image/ab6765630000f68d1d03799a5d846fdb2bb221f7","width":64},{"height":300,"url":"https://i.scdn.co/image/ab67656300005f1f1d03799a5d846fdb2bb221f7","width":300},{"height":640,"url":"https://i.scdn.co/image/ab6765630000ba8a1d03799a5d846fdb2bb221f7","width":640}]},"description":"Dr David M. Epstein is the co-founder and president of PairX Bio, a company that specializes in the next generation of cancer selective biologics.  In this episode, David shares his experience and journey from working in various biotech companies and big pharma institutions to eventually building his own companies. One of these is Pairx Bio, a company specializing in the next generation of cancer biologics. David stresses the importance of how being able to follow the science and being transparent and open with the discussions on data collected from research projects plays a key role in the success of a company. He also touches on the success of targeted cancer therapies, some of which has led to an increase in lifespan, as well as the limitations in terms of the range of diseases that can be treated with this therapy. He also highlights the future of therapeutics in general, discussing the push in biotherapeutics and immunotherapeutics and expanding the horizon where these new innovative treatments can be effective. Lastly, he touches on the importance of how to handle IP matters and protecting one’s IP.  Host: Aakash S/O Naresh Kumar Editors: Hana Maldivita Tambrin, Dillon Chew, Jessie Wong, John Joson Ng The show notes and transcripts for the episode can be found on nucleatesingapore.substack.com. For feedback or recommendations on who we should talk to next, please reach out to the team via singapore@nucleate.org.  01:01 - Introduction 05:10 - Origins of Pairx Bio and Key Characteristics For a Successful Startup 13:18 - Key differences in the process of IP patenting 18:22 - Singapore VS USA Biotech Ecosystems 20:51 - Future of Singapore’s Biotech Ecosystem","duration":{"totalMilliseconds":1526022},"id":"0UJJHU66Kz4yokF1I1jGly","mediaTypes":["AUDIO"],"name":"Innovating new cancer-selective biologics with PairX Bio’s Dr. David M. Epstein","playability":{"playable":true,"reason":"PLAYABLE"},"playedState":{"playPositionMilliseconds":0,"state":"NOT_STARTED"},"podcastV2":{"__typename":"PodcastResponseWrapper","data":{"__typename":"Podcast","coverArt":{"sources":[{"height":64,"url":"https://i.scdn.co/image/ab6765630000f68de5e4b83bb352c2e59589182a","width":64},{"height":300,"url":"https://i.scdn.co/image/ab67656300005f1fe5e4b83bb352c2e59589182a","width":300},{"height":640,"url":"https://i.scdn.co/image/ab6765630000ba8ae5e4b83bb352c2e59589182a","width":640}]},"name":"Nucleate Singapore Pulse","showTypes":[],"uri":"spotify:show:4P4f5d48U1QSG69bGkf4bi"}},"releaseDate":{"isoString":"2024-11-16T06:18:00Z"},"restrictions":{"paywallContent":false},"uri":"spotify:episode:0UJJHU66Kz4yokF1I1jGly"},{"__typename":"Episode","audio":{"items":[{"fileId":"6cdcc5a0e82a483138675f31a245987ce9a35172","format":"MP4_128_DUAL","url":"https://p.scdn.co/mp3-preview/6cdcc5a0e82a483138675f31a245987ce9a35172"},{"fileId":"3fe53297d20fe7f5d55f6a8b67db926589153944","format":"OGG_VORBIS_96","url":"https://p.scdn.co/mp3-preview/3fe53297d20fe7f5d55f6a8b67db926589153944"},{"fileId":"297db2e9abd1e67a1258e7d7be2944dc23422365","format":"MP4_128","url":"https://p.scdn.co/mp3-preview/297db2e9abd1e67a1258e7d7be2944dc23422365"},{"fileId":"bc83b3c291930f3f516528b3d855c3f16fb9e9ad","format":"MP4_128_CBCS","url":"https://p.scdn.co/mp3-preview/bc83b3c291930f3f516528b3d855c3f16fb9e9ad"},{"fileId":"ab0de984acdd2420e6639d61a58029249f8a8e1c","format":"AAC_24","url":"https://p.scdn.co/mp3-preview/ab0de984acdd2420e6639d61a58029249f8a8e1c"}]},"contentRating":{"label":"NONE"},"coverArt":{"sources":[{"height":64,"url":"https://i.scdn.co/image/ab6765630000f68dba7f3c37ce5e9a60189bbd6a","width":64},{"height":300,"url":"https://i.scdn.co/image/ab67656300005f1fba7f3c37ce5e9a60189bbd6a","width":300},{"height":640,"url":"https://i.scdn.co/image/ab6765630000ba8aba7f3c37ce5e9a60189bbd6a","width":640}]},"description":"In our first episode recorded live in front of an audience, we’re with Lovisa Afzelius, the General Partner of the European branch of Flagship Pioneering 🇸🇪  We talk about Flagship, including its EU activities. We also talk about company-building and Lovisa’s personal journey to be one of the leading Swedish leaders in biotech.  ⭐️ ABOUT THE SPEAKER  Lovisa is an icon in the EU biotech and pharma world, having been a CEO, co-founder, president, board chairman, and executive director in many emerging companies. Joining Flagship in 2020, she became the founding CEO of Alltrna, and co-founded/CEO of Apriori Bio, Metaphore Biotechnologies, and Prologue Medicines. Lovisa has received many accolades. A few include being listed on Inc. Magazine’s Female Founders 250 List in 2024, 2023 she featured in the PharmaVoice 100 list of life science industry leaders.   🔗 LINKS MENTIONED  - Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial: https://investors.modernatx.com/news/news-details/2022/Moderna-and-Merck-Announce-mRNA-4157V940-an-Investigational-Personalized-mRNA-Cancer-Vaccine-in-Combination-with-KEYTRUDAR-pembrolizumab-Met-Primary-Efficacy-Endpoint-in-Phase-2b-KEYNOTE-942-Trial/default.aspx?os=vb&ref=app - Agnete Fredriksen, Nykode | Being one of the top 50 women in 🇪🇺 Bio | E07: https://flot.bio/episode/agnete-fredriksen-top-women-bio/ - BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024: https://investors.biontech.de/news-releases/news-release-details/biontech-present-clinical-data-updates-across-mrna-and - Nouscom Raises €67.5 Million ($72 Million) In Oversubscribed Series C Financing Round: https://nouscom.com/2023/11/14/nouscom-raises-e67-5-million-72-million-in-oversubscribed-series-c-financing-round-2-2/ - Otello Stampacchia, Omega Funds 🇮🇹 | Competition, Boston & Pasta | E18: https://flot.bio/episode/otello-stampacchia-omega-funds/  📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/lovisa-afzelius-flagship-pioneering/  💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme  ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!  🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio  🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.  🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free.  ⏰ TIMESTAMPS [00:00:00] Intro [00:02:08] Flagship Pioneering and their EU biotech initiatives [00:06:18] Being creative in many biotech spheres [00:08:37] Why invest 50m in first seed Series A every time? [00:11:42] The Flagship Pioneering business model: invest early [00:15:57] VC-created vs founder-led biotechs [00:17:46] Raising one of the largest biotech funds [00:19:19] Flagship Pioneering’s biggest returns [00:22:36] AI & biotech [00:26:31] What does success mean to Flagship Pioneering [00:29:20] How to help biotech spinoffs grow and advice for women to be biotech leaders  [00:34:03] How to move from computational to translation sciences & bring drugs to market faster [00:37:14] What can the EU learn from the US to create biotechs [00:40:36] How do you bridge the gap between biotech company creation in the US vs EU [00:43:07] Lessons for an early-stage biotech career [00:47:18] How to attract the best biotech talent [00:48:38] Moving to Boston [00:52:13] Quickfire [00:55:41] Thanks for listening","duration":{"totalMilliseconds":3556762},"id":"1rcGWndlmKW8omXaixbaz9","mediaTypes":["VIDEO","AUDIO"],"name":"Lovisa Afzelius, Flagship Pioneering 🇸🇪 | Company building, AI | E25","playability":{"playable":true,"reason":"PLAYABLE"},"playedState":{"playPositionMilliseconds":0,"state":"NOT_STARTED"},"podcastV2":{"__typename":"PodcastResponseWrapper","data":{"__typename":"Podcast","coverArt":{"sources":[{"height":64,"url":"https://i.scdn.co/image/ab6765630000f68d689c4583ead7a8f6588a8f9f","width":64},{"height":300,"url":"https://i.scdn.co/image/ab67656300005f1f689c4583ead7a8f6588a8f9f","width":300},{"height":640,"url":"https://i.scdn.co/image/ab6765630000ba8a689c4583ead7a8f6588a8f9f","width":640}]},"name":"Flot.bio x Philip Hemme","showTypes":[],"uri":"spotify:show:5QjEXf2zKv8oaEcLR934fV"}},"releaseDate":{"isoString":"2024-11-18T13:31:00Z"},"restrictions":{"paywallContent":false},"uri":"spotify:episode:1rcGWndlmKW8omXaixbaz9"},{"__typename":"Episode","audio":{"items":[{"fileId":"e9be1181e0e3fe9aeac51be88cc4ad9f16d86486","format":"MP4_128_DUAL","url":"https://p.scdn.co/mp3-preview/e9be1181e0e3fe9aeac51be88cc4ad9f16d86486"},{"fileId":"51561d64d7dcd913105752435feed08aca2d7c18","format":"OGG_VORBIS_96","url":"https://p.scdn.co/mp3-preview/51561d64d7dcd913105752435feed08aca2d7c18"},{"fileId":"978acb52d941d5aff5e040487b34fe086d4c19ba","format":"MP4_128","url":"https://p.scdn.co/mp3-preview/978acb52d941d5aff5e040487b34fe086d4c19ba"},{"fileId":"7847ab7b6e1eddcb58b6b0affd00afa2f647e3a8","format":"MP4_128_CBCS","url":"https://p.scdn.co/mp3-preview/7847ab7b6e1eddcb58b6b0affd00afa2f647e3a8"},{"fileId":"4ec9acfa717b6804262d87a988ed1f554427da77","format":"AAC_24","url":"https://p.scdn.co/mp3-preview/4ec9acfa717b6804262d87a988ed1f554427da77"}]},"contentRating":{"label":"NONE"},"coverArt":{"sources":[{"height":64,"url":"https://i.scdn.co/image/ab6765630000f68d8ab88a3bae40130baaf47c2f","width":64},{"height":300,"url":"https://i.scdn.co/image/ab67656300005f1f8ab88a3bae40130baaf47c2f","width":300},{"height":640,"url":"https://i.scdn.co/image/ab6765630000ba8a8ab88a3bae40130baaf47c2f","width":640}]},"description":"How is the Rice Bioengineering Capstone Design course integral in the development of students in the bioengineering department and across all engineering disciplines? How do Rice students benefit from being at an institution that prioritizes premier teaching and research?Dr. Sabia Zehra Abidi is an assistant teaching professor in bioengineering at Rice with expertise in stem cell research, microfluidics, and disease treatment. Dr. Abidi shares her journey through the field, from research to teaching, driven by her fascination with cellular communication and tissue engineering.Sabia and host David Mansouri discuss how Rice is engaging students in bioengineering. Sabia also shares her involvement with students in various innovative programs, including through the Medical Humanities Research Institute.David asks Sabia about her insights on the intersection of bioengineering and artificial intelligence, highlighting the potential and also the challenges of AI in healthcare. Additionally, she shares insights into her mentorship roles, advising on medical device projects, and the unique aspects of undergraduate education at Rice University.Let us know you’re listening by filling out this form. We will be randomly selecting listeners to receive Beyond the Hedges Swag every month.Episode Guide:03:36 Current Focus and Excitement in Bioengineering05:26 Intersection of Bioengineering and AI07:50 Teaching and Student Innovation12:09 Capstone Design and Student Achievements20:49 Transition from Research to Teaching23:37 Rapid Fire Questions and ConclusionBeyond The Hedges is a production of the Office of Alumni Relations at Rice University and is produced by University FM.Show Links:Rice Department of BioengineeringRice AlumniAssociation of Rice Alumni | FacebookRice Alumni (@ricealumni) | X (Twitter)Association of Rice Alumni (@ricealumni) | Instagram Host Profiles:David Mansouri | LinkedInDavid Mansouri ’07 | Alumni | Rice UniversityDavid Mansouri (@davemansouri) | XDavid Mansouri | TNScoreGuest Profiles:Faculty Profile at RiceLinkedInTwitter/XResearchGate ProfileEpisode Quotes:Bringing medical humanities into bioengineering to solve human-centered problems08:30: I think the power of medical humanities is approaching problems from a perspective that we're not necessarily trained in. As bioengineers, we look at things in terms of, I don't know, here's the biology side, here's the engineering approach, here are the equations. And with medical humanities, you're really thinking about the experience; you're thinking about these people, where they're coming from, really getting into that human-centered design aspect. And so, that's the power of combining with medical humanities, for example, with this grant that we have together, where students, these bioengineers, actually go into hospitals, and they're looking for areas for innovation. And they're trained to look at these spaces in a certain way, but with technology tools from medical humanities. They can really dig into problems and understand, \"Okay, what are the human-related issues here? And are we solving the right problem?\"What makes the bioengineering program at Rice special?16:25: Rice's undergraduate bioengineering program is very special in that there are many opportunities for students to interact with the material in different ways, both in-depth and breadth.Teaching as a path to profound impact and lifelong learning23:09: In terms of teaching, I feel like you have the ability to impact people in a way that is profound. Like sometimes it's just a small conversation here and there. And then you can also create these programs, right? So these amazing programs that are training students do great.","duration":{"totalMilliseconds":1601536},"id":"5zzeqGhr6lYBByXrJMjzw7","mediaTypes":["AUDIO"],"name":"Innovations in Bioengineering and Education feat. Dr. Sabia Zehra Abidi","playability":{"playable":true,"reason":"PLAYABLE"},"playedState":{"playPositionMilliseconds":0,"state":"NOT_STARTED"},"podcastV2":{"__typename":"PodcastResponseWrapper","data":{"__typename":"Podcast","coverArt":{"sources":[{"height":64,"url":"https://i.scdn.co/image/ab6765630000f68df16223205b3c6cbf89add344","width":64},{"height":300,"url":"https://i.scdn.co/image/ab67656300005f1ff16223205b3c6cbf89add344","width":300},{"height":640,"url":"https://i.scdn.co/image/ab6765630000ba8af16223205b3c6cbf89add344","width":640}]},"name":"Beyond the Hedges","showTypes":[],"uri":"spotify:show:2fYPwaB93AlHda2iRMXJMK"}},"releaseDate":{"isoString":"2024-11-13T10:00:00Z"},"restrictions":{"paywallContent":false},"uri":"spotify:episode:5zzeqGhr6lYBByXrJMjzw7"},{"__typename":"Episode","audio":{"items":[{"fileId":"1a3ad557cd7e492652c5922af02e79112d43bc5d","format":"MP4_128_DUAL","url":"https://p.scdn.co/mp3-preview/1a3ad557cd7e492652c5922af02e79112d43bc5d"},{"fileId":"18a4dd02ebec65eb3455bb03c3c30be76bb3e16c","format":"MP4_128","url":"https://p.scdn.co/mp3-preview/18a4dd02ebec65eb3455bb03c3c30be76bb3e16c"},{"fileId":"b3f10de536caf089a487629965424d23437270e9","format":"OGG_VORBIS_96","url":"https://p.scdn.co/mp3-preview/b3f10de536caf089a487629965424d23437270e9"},{"fileId":"aa86844c79152e23cf5da1d8a2df803969e31345","format":"AAC_24","url":"https://p.scdn.co/mp3-preview/aa86844c79152e23cf5da1d8a2df803969e31345"},{"fileId":"2328342981fa3f0763118779dbca5592da824651","format":"MP4_128_CBCS","url":"https://p.scdn.co/mp3-preview/2328342981fa3f0763118779dbca5592da824651"}]},"contentRating":{"label":"NONE"},"coverArt":{"sources":[{"height":64,"url":"https://i.scdn.co/image/ab6765630000f68dda59417ed749665be5e8620b","width":64},{"height":300,"url":"https://i.scdn.co/image/ab67656300005f1fda59417ed749665be5e8620b","width":300},{"height":640,"url":"https://i.scdn.co/image/ab6765630000ba8ada59417ed749665be5e8620b","width":640}]},"description":"What does it take to move from cutting-edge academic research to launching a biotech company that could transform medicine? In this week’s episode of Founded & Funded, Madrona Partner Chris Picardo sat down with Jamie Lazarovitz, CEO and co-founder of Archon Biosciences, to uncover the story behind their groundbreaking protein-based biologics and their unique Antibody Cages (AbCs). From bootstrapping deep tech investments as a student to navigating the challenges of commercializing revolutionary science, Jamie shares the pivotal moments, tough decisions, and key lessons that led to Archon’s creation. This isn’t just a story for biotech enthusiasts — every founder can take away valuable insights on: 1) Asking for help and building teams with complementary skills — no founder succeeds alone. 2) Applying AI thoughtfully — it’s a tool, not a magic wand. 3) Patience — ensure your foundation is strong before scaling. 4) Partnering with investors you trust and who align with your mission. 5) Setting a high bar for talent and culture — great people build great companies. 6) Communicating your differentiation — make your value clear to all stakeholders.  Full Transcript:  https://www.madrona.com/archon-unlocks-antibodies-with-ai-jamie-lazarovits   Chapters:  (00:00) Introduction  (00:55) Jamie Lazarovitz's Journey from Deep Tech to Biotech (01:45) Early Ventures and Lessons Learned (05:03) The Motivation Behind Jamie’s Biotech Passion (07:40) Joining the Institute for Protein Design - David Baker (09:40) Meeting Co-Founder George Ueda and the Birth of Archon (12:46) Revolutionary Protein Design at Archon: Antibody Cages (AbCs) (25:23) The Role of AI in Protein Design (27:50) Building a Successful Biotech Company (38:47) Future Prospects","duration":{"totalMilliseconds":2437703},"id":"6j6lfVLJmg7tuSaHZnXJsR","mediaTypes":["AUDIO"],"name":"Archon's Jamie Lazarovits on Unlocking the Full Power of Antibodies With AI","playability":{"playable":true,"reason":"PLAYABLE"},"playedState":{"playPositionMilliseconds":0,"state":"NOT_STARTED"},"podcastV2":{"__typename":"PodcastResponseWrapper","data":{"__typename":"Podcast","coverArt":{"sources":[{"height":64,"url":"https://i.scdn.co/image/ab6765630000f68dda59417ed749665be5e8620b","width":64},{"height":300,"url":"https://i.scdn.co/image/ab67656300005f1fda59417ed749665be5e8620b","width":300},{"height":640,"url":"https://i.scdn.co/image/ab6765630000ba8ada59417ed749665be5e8620b","width":640}]},"name":"Founded & Funded","showTypes":[],"uri":"spotify:show:2ePgKWebuH5XfcoUpSi330"}},"releaseDate":{"isoString":"2024-11-13T11:00:00Z"},"restrictions":{"paywallContent":false},"uri":"spotify:episode:6j6lfVLJmg7tuSaHZnXJsR"},{"__typename":"Episode","audio":{"items":[{"fileId":"2d2a5f9b98f7317d2b457b02daa96a9484ee0abb","format":"MP4_128_DUAL","url":"https://p.scdn.co/mp3-preview/2d2a5f9b98f7317d2b457b02daa96a9484ee0abb"},{"fileId":"fea368f1dfc7ff4b8de7ebff432a1a10d291ae6a","format":"OGG_VORBIS_96","url":"https://p.scdn.co/mp3-preview/fea368f1dfc7ff4b8de7ebff432a1a10d291ae6a"},{"fileId":"8c74097c7051578dd2307bcf65d2ca45394cdb9f","format":"MP4_128","url":"https://p.scdn.co/mp3-preview/8c74097c7051578dd2307bcf65d2ca45394cdb9f"},{"fileId":"cc032c468b8775798aaabf56b480a3a7dd5665dc","format":"AAC_24","url":"https://p.scdn.co/mp3-preview/cc032c468b8775798aaabf56b480a3a7dd5665dc"},{"fileId":"70bddd8102b3e74f4e828f627175a2ece5a6c321","format":"MP4_128_CBCS","url":"https://p.scdn.co/mp3-preview/70bddd8102b3e74f4e828f627175a2ece5a6c321"}]},"contentRating":{"label":"NONE"},"coverArt":{"sources":[{"height":64,"url":"https://i.scdn.co/image/ab6765630000f68dc0dd02098e8cc6ced38b19f0","width":64},{"height":300,"url":"https://i.scdn.co/image/ab67656300005f1fc0dd02098e8cc6ced38b19f0","width":300},{"height":640,"url":"https://i.scdn.co/image/ab6765630000ba8ac0dd02098e8cc6ced38b19f0","width":640}]},"description":"Bacteriophage technology is being used to address acne, eczema, and other dysbiotic skin concerns. Some microbiology companies are working with endolysins (proteins produced by phages), others are focused on formulating skincare with phages themselves.  This week on the CosmoFactory podcast, we consider possible cosmetic industry applications for bacteriophage technology. Our guest is Milan Bunata, Business Director of FagoFarma, a biotech company specialized in phage-based preparations for use in the cosmetics, pharma, and veterinary industries. Based in the Czech Republic, FagoFarma was established in 2013. And this year, in an effort to both educate consumers about phage-based skincare and to gather feedback, the company launched a consumer acne care product called FagoCare Gel.  If you appreciate this episode, SHARE it with a colleague, SUBSCRIBE to the CosmoFactory podcast & please LEAVE US A REVIEW today. With your help, even more cosmetic industry professionals can discover the inspiring interviews we share on CosmoFactory! ABOUT CosmoFactoryBeauty industry stakeholders listen to the CosmoFactory podcast for inspiration and for up-to-date information on concepts, tactics, and solutions that move business forward. CosmoFactory – Ideas to Innovation is a weekly interview series for cosmetics and personal care suppliers, finished product brand leaders, retailers, buyers, importers, and distributors. Each Tuesday, CosmoFactory guests share experiences, insights, and exclusive behind-the-scenes details—which makes this not only a must-listen B2B podcast but an ongoing case study of our dynamic industry. Guests are actively working in hands-on innovation roles along the beauty industry supply chain; they specialize in raw materials, ingredients, manufacturing, packaging, and more. They are designers, R&D or R&I pros, technical experts, product developers, key decision makers, visionary executives. HOST Deanna UtroskeCosmetics and personal care industry observer Deanna Utroske hosts the CosmoFactory podcast. She brings an editorial perspective and a decade of industry expertise to every interview. Deanna is also Editor of the Beauty Insights newsletter and a supply-side positioning consultant. She writes the Global Perspectives column for EuroCosmetics magazine, is a former Editor of CosmeticsDesign, and is known globally for her ability to identify emerging trends, novel technologies, and true innovation in beauty. A PRODUCTION OF Cosmoprof Worldwide BolognaCosmoFactory is the first podcast from Cosmoprof Worldwide Bologna, taking its place among the best B2B podcasts serving the global beauty industry.   Cosmoprof Worldwide Bologna is the most important beauty trade show in the world. Dedicated to all sectors of the industry, Cosmoprof Worldwide Bologna welcomes over 250,000 visitors from 150 countries and regions and nearly 3,000 exhibitors to Bologna, Italy, each year. It’s where our diverse and international industry comes together to build business relationships and to discover the best brands and newest innovations across consumer beauty, professional beauty, and the entire supply chain. The trade show includes a robust program of exclusive educational content, featuring  executives and key opinion leaders from every sector of the cosmetics, fragrance, and personal care industry. Cosmoprof Worldwide Bologna is the most important event of the Cosmoprof international network, with exhibitions in Asia (Hong Kong), the US (Las Vegas and Miami), India (Mumbai) and Thailand (Bangkok). Thanks to its global exhibitions Cosmoprof connects a community of more than 500,000 beauty stakeholders and 10,000 companies from 190 countries and regions. Learn more today at Cosmoprof.com ","duration":{"totalMilliseconds":1700559},"id":"5K4Mk6sSN1GXkAFp1Z4yIn","mediaTypes":["AUDIO"],"name":"Phage-Based Skincare, featuring FagoFarma Business Director Milan Bunata","playability":{"playable":true,"reason":"PLAYABLE"},"playedState":{"playPositionMilliseconds":0,"state":"NOT_STARTED"},"podcastV2":{"__typename":"PodcastResponseWrapper","data":{"__typename":"Podcast","coverArt":{"sources":[{"height":64,"url":"https://i.scdn.co/image/ab6765630000f68dc0dd02098e8cc6ced38b19f0","width":64},{"height":300,"url":"https://i.scdn.co/image/ab67656300005f1fc0dd02098e8cc6ced38b19f0","width":300},{"height":640,"url":"https://i.scdn.co/image/ab6765630000ba8ac0dd02098e8cc6ced38b19f0","width":640}]},"name":"COSMOFACTORY","showTypes":[],"uri":"spotify:show:0sWooyMqkfDRrGRgnDSVkH"}},"releaseDate":{"isoString":"2024-11-12T13:00:00Z"},"restrictions":{"paywallContent":false},"uri":"spotify:episode:5K4Mk6sSN1GXkAFp1Z4yIn"},{"__typename":"Episode","audio":{"items":[{"fileId":"9d37ebfe5d18f6960beca4192d549895faa890a3","format":"MP4_128","url":"https://p.scdn.co/mp3-preview/9d37ebfe5d18f6960beca4192d549895faa890a3"},{"fileId":"b2414b640468da36bdc2600968aa2439be4bf632","format":"MP4_128_CBCS","url":"https://p.scdn.co/mp3-preview/b2414b640468da36bdc2600968aa2439be4bf632"},{"fileId":"8b43e8156e30ce9e8ca4397d78ce4f4a7ba66c4a","format":"MP4_128_DUAL","url":"https://p.scdn.co/mp3-preview/8b43e8156e30ce9e8ca4397d78ce4f4a7ba66c4a"},{"fileId":"483219d0b89788c9f262c7b011bfdaa9ebc983ed","format":"AAC_24","url":"https://p.scdn.co/mp3-preview/483219d0b89788c9f262c7b011bfdaa9ebc983ed"},{"fileId":"8d88d5f3e3e721cbdf23ea9562d0bee8a48a35c9","format":"OGG_VORBIS_96","url":"https://p.scdn.co/mp3-preview/8d88d5f3e3e721cbdf23ea9562d0bee8a48a35c9"}]},"contentRating":{"label":"NONE"},"coverArt":{"sources":[{"height":64,"url":"https://i.scdn.co/image/ab6765630000f68db5b8a23bc8b9332e76ee3c46","width":64},{"height":300,"url":"https://i.scdn.co/image/ab67656300005f1fb5b8a23bc8b9332e76ee3c46","width":300},{"height":640,"url":"https://i.scdn.co/image/ab6765630000ba8ab5b8a23bc8b9332e76ee3c46","width":640}]},"description":"This week, I spoke with Natalie Nairn, co-founder and CEO of Cyclera Therapeutics. Natalie is also a Termeer Fellow, and listeners of this podcast know how much I love the Termeer Foundation. We discuss her transition from chemical engineering to biomedical applications. She describes her unexpected path into the fun and volatile startup space, which led to her founding Cyclera. Natalie explains the importance of focusing in biotech development, the promising applications of Cyclera's technology in CNS therapeutics, and the challenges and opportunities in the current funding landscape. She also highlights the value of the Termeer fellowship in her career, the contrast between Boston and Seattle's biotech scenes, and the essential aspects of leadership and team cohesion. Finally, Natalie discusses her future goals for Cyclera and offers valuable advice for aspiring biotech founders.Get Natalie's recommended book! The Book of Delights: EssaysCYpHER: catalytic extracellular targeted protein degradation with high potency and durable effect | Nature CommunicationsConnect with Natalie on LinkedIn!Learn more about Cyclera TherapeuticsConnect with us!Link In with CarinaSubscribe here:AppleSpotifyGoogle PodcastRSS feedLearn more about Recruitomics ConsultingCheck out our reading listDownload our free startup resources guide to grow your biotech efficientlyIf you're on the job market, visit the Collaboratory Career Hub 00:00 Introduction and Early Aspirations00:33 Journey into Biomedical Engineering01:19 First Startup Experience03:40 Founding Cyclera05:02 Focus on CNS Therapeutics13:35 Challenges and Strategies in Biotech15:39 The Termeer Foundation Fellowship21:26 Biotech Networks: Boston vs. Seattle26:50 Future of Cyclera and Personalized Medicine32:45 Conclusion and Final Thoughts","duration":{"totalMilliseconds":2262420},"id":"59rt7QUSDTAIwMowAQBxpl","mediaTypes":["AUDIO"],"name":"Trust, Teamwork, and Innovation, with Natalie Nairn, Co-founder and CEO of Cyclera Therapeutics","playability":{"playable":true,"reason":"PLAYABLE"},"playedState":{"playPositionMilliseconds":0,"state":"NOT_STARTED"},"podcastV2":{"__typename":"PodcastResponseWrapper","data":{"__typename":"Podcast","coverArt":{"sources":[{"height":64,"url":"https://i.scdn.co/image/ab6765630000f68d2b52149bed7fbc0fefbe603e","width":64},{"height":300,"url":"https://i.scdn.co/image/ab67656300005f1f2b52149bed7fbc0fefbe603e","width":300},{"height":640,"url":"https://i.scdn.co/image/ab6765630000ba8a2b52149bed7fbc0fefbe603e","width":640}]},"name":"Building Biotechs","showTypes":[],"uri":"spotify:show:2BtCW9gsMYabOA9fdTt6bn"}},"releaseDate":{"isoString":"2024-11-08T20:54:00Z"},"restrictions":{"paywallContent":false},"uri":"spotify:episode:59rt7QUSDTAIwMowAQBxpl"}],"uri":"spotify:episode:0BUwq1DLQg9KAFG1jaV4mC","status":"LOADED"},"similarPlaylists":{"status":"UNAVAILABLE"},"similarAlbums":{"status":"UNAVAILABLE"},"popularEpisodes":{"status":"UNAVAILABLE"}},"playlistRecommendedTracks":{"playlist":{"status":"UNAVAILABLE"}},"concertHub":{"concertFeed":null,"location":null},"masthead":{"isCrawlerBot":false}}</script><script id="remote-configuration" type="text/plain">eyIjdiI6IjEiLCJlbmFibGVJMThuUm91dGVzIjoidmFyaWFudCIsImRpc2FibGVVbmF1dGhMeXJpY3NDVEEiOnRydWUsIiNjb25maWd1cmF0aW9uQXNzaWdubWVudElkIjoiMmVjZmM0MTEtNDg2Mi04MDc1LThiMWMtOTdhYTY5YmM2MDdhOjAiLCIjZ3JvdXBJZHMiOnsiZW5hYmxlSTE4blJvdXRlcyI6MTEwMjY2MSwiZGlzYWJsZVVuYXV0aEx5cmljc0NUQSI6MTE4NjU0MX0sIiNmZXRjaFRpbWVNaWxsaXMiOjE3MzI0MTA5MTA4OTAsIiNjb250ZXh0SGFzaCI6Ijk2MDdiZjYxMmQ5NTBhYzUifQ==</script><script src="https://open.spotifycdn.com/cdn/build/mobile-web-player/mobile-web-player.0a708a8c.js"></script><script src="https://open.spotifycdn.com/cdn/build/mobile-web-player/vendor~mobile-web-player.13b4135a.js"></script></body></html>